Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

100% positive feedbacks

Martin Signer

Managing Director at 4Finance
Languages: English, German, French, Spanish

300 connections

Notes

Martin Signer's personal:

Profile summary

Martin Signer holds a Masters degree (lic. oec. publ.) in quantitative finance from the economic faculty of the University of Zurich. Prior to his activity and founding 4Finance, he was responsible for the market risk management of the Clariden Bank. Besides his activity with 4Finance Martin Signer is also active as a university lecturer and author of several publications. Martin Signer was born in Zug. His hobbies are sports (tennis, and golf), chess and music.

Show more

Recent Activities

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

4 hours ago

Fighting COVID-19: Does blockchain have a role to play?

Article about Fighting COVID-19: Does blockchain have a role to play?

 



More than any event in our lifetime, the COVID-19 global pandemic underscores the interconnectedness of our world. It also throws a very harsh light on a troubling fact: at a time when we need rapid, coordinated action and collaboration, massive amounts of critical information continue to be trapped in hardened data silos and legacy processes.

Now more than ever, we need a trusted platform to automate outdated ways of working, rapidly piece together disparate data sets, and unlock actionable insights to navigate through this crisis — and prepare for the long recovery ahead in a changed world.

Blockchain technology may offer opportunities to increase trust & transparency -- but it's not a silver bullet. Rather, it is part of a broader digitization strategy that must be evaluated and deployed responsibly and holistically.

SmartMoneyMatch gives support by finding the right service provider with the required expertise in the areas of FinTechICTlegal & compliancedue diligencefund servicesbankingconsultingsales & marketinginsurance, PropTech, and general services like accounting and HR

Also, participation in the right events and recruiting the right candidates with our job board might help. 

 
  
 
The taxonomy of crypto assets

To list and search investments/investors the asset class classification (taxonomy) of crypto assets is:

•     Cryptocurrencies (synonymous to payment token) such as bitcoin, litecoin, libra, ether, etc, are in the asset class of commodities/cryptocurrencies.

•    Investment in security tokens (including stablecoins) that derive their value from a tradable asset according to the underlying investment. Typically it will be equity, private capital (this includes private equity, venture capital, private debt, infrastructure, private equity real estate, collectives, special situations, intellectual property, and secondaries, etc.), but can also be real estate, multi-asset, fixed-income, commodities/cryptocurrencies, hedge funds, or insurance-linked-securities.

•    Utility tokens are simply app coins or user tokens. They enable future access to the products or services offered by a company. If used for investing, they will be treated according to their main characteristics as a cryptocurrency or a security token.

•    Trading strategies belong to the asset class of hedge fund/trading.

 

 

 
 
 
 
 

 

 

 

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 days ago

Help Nepal fighting COVID-19

Gopal Shah from Nepal is requesting donations to fight COVID-19 and I encourage it:

As he mentions:

"Covid19 is now hitting all over the country, but together we have the power to act. show your solidarity by donation for the individual and family in Nepal who are suffering the brunt of the virus s health-related , social economic impact We appeal to you for help show your solidarity with those who are most severely affect by coronavirus pandemic, direct and indirect people, especially suffering,poverty, People who are poor, labor, orphan disables food, they are hungry.

Now 14,000 people are directly affected by COVID-19, 32 people die, in lockdown long time 1105 people suicide case that we are humble request super your heart, etc"

 

Help directly to

Gopal Bahadur Shah

Account no IBAN (050100005338524)

IBAN DE 96512305000018042400

Swift code BIC (BOKLNPKA)

Bank of Kathmandu Kathmandu metropolitan city 29

Thamel Kathmandu Nepal


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 days ago

TGI Enters into Definitive Agreement to Acquire Interest in Lucent Energy Management

TGI SOLAR POWER GROUP INC. (OTCMarkets: TSPG) “TGI”, a diversified technology company, announced today that it has entered into a definitive agreement to acquire an interest in Lucent Energy Management. Lucent provides renewable energy services and energy efficiency installations for commercial and residential energy consumers.
As a direct installer, they offer system engineering, procurement, and construction (EPC) of renewable energy systems. Currently Lucent has offices in New Jersey, which covers the Northeast, and in South Carolina, which covers Southeastern states. The transaction is subject to customary closing conditions
and is expected to close in the third quarter.
Mr. Steven Schwartz, CEO and Chairman of Lucent, will oversee solar and other green
developments of TGI; he comes with years of experience and brings with him a staff of
50+ developers, salespeople, engineers and solar installers. TGI plans to bring in
additional sales staff and trainees from a pool of interns. An expansion plan also calls
for strategic expansion into Western states of the USA; the target markets being
California and Texas to start with.
Chairman and Chief Executive Officer of Lucent, said, "We are thrilled to expand our
partnership with TGI management team. Lucent's management wants to successfully
reposition the company and strengthen its financial performance. Now, under the
guidance of TGI, with their deep experience in the energy industry and capital
allocation, we are excited to participate in the next phase of Lucent’s growth. I am
confident that the TGI team is the best partner for Lucent for the long-term."
TGI management is pleased with its decision to make Mr. Schwartz the head of the
Solar Energy and Storage Division. His leadership will enhance TGI’s green sustainable
energy developments.
 
About TGI Solar
TGI SOLAR POWER GROUP INC. is a diversified holding company.
TGI's strategy is to acquire innovative and patented technologies, components,
processes, designs and methods with commercial value that will give competitive
market advantage and generate shareholder value.

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 days ago

How countries pay for impatience with COVID-19 measures

There are options for:

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 days ago

INVIBES ADVERTISING ETEND SON EMPREINTE EUROPEENNE AU BENELUX

INVIBES ADVERTISING, société spécialisée dans la publicité intégrée au cœur de contenus
éditoriaux des sites media (in-feed), consolide son empreinte européenne en s’implantant au Benelux.
La société ouvre un bureau à Anvers auquel seront affiliées deux antennes à Bruxelles et à Amsterdam.
Après la France, l'Espagne, l'Allemagne, l’Italie, la Suisse et le Royaume-Uni, INVIBES ADVERTISING s’implante dans deux nouveaux pays en Europe en Belgique et aux Pays-Bas et totalise ainsi à date une présence dans huit pays européens.
Tim VERGOUTS est nommé Directeur commercial d’INVIBES Benelux et sera basé à
Anvers. Il aura pour mission de développer les partenariats éditeurs et de promouvoir
les formats in-feed auprès des annonceurs et agences média. Avant de rejoindre INVIBES
ADVERTISING, Tim a travaillé 8 ans pour Mood Media, le leader mondial des solutions
multimédias en magasin, et occupait depuis près de 3 ans les fonctions de Sales Manager
au sein de l’entreprise.
Tim VERGOUTS, Directeur commercial d’INVIBES Benelux déclare à cette occasion :
« Je suis très enthousiaste de rejoindre INVIBES ADVERTISING, l’une des entreprises les
plus innovantes du secteur de la publicité digitale en Europe, et de participer à son
développement international. »
Nicolas POLLET, CEO et co-fondateur d’INVIBES ADVERTISING, ajoute : « Le Benelux est une région importante d’Europe en matière d’investissements publicitaires et représente à ce titre une nouvelle zone de croissance dans le cadre de notre expansion internationale. Je suis très heureux d’accueillir Tim au sein l’équipe et suis convaincu que son expertise sera un atout décisif dans le développement rapide de l’entreprise sur cette zone stratégique pour le Groupe. »


A propos d’INVIBES ADVERTISING
Créée en 2011, INVIBES ADVERTISING est une société technologique du secteur de la publicité digitale. Elle a développé une solution publicitaire non intrusive et efficace, qui s’appuie sur un format in-feed, intégré dans les contenus média, inspiré des réseaux sociaux et optimisé pour une diffusion sur un réseau fermé de sites média :
Bertelsmann, Hearst, Lagardère et beaucoup d’autres. Ses clients sont par ailleurs de grandes marques telles que Mercedes, Samsung, Air France et IBM. INVIBES ADVERTISING est cotée sur Euronext Growth à Paris (Mnémonique : ALINV – ISIN : BE0974299316).


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

4 days ago

Swiss suicide rate halved in the last 30 years

Once some positive developments from Switzerland. As it was notorious for very high suicide rates than halved in the last 30 years and is now below the world average.

E.g. South Korea is on the wrong track.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

4 days ago

NOXXON ANNONCE LA NOMINATION DE OSCAR IZEBOUD AU CONSEIL DE SURVEILLANCE ET PRESENTE LES RESULTATS DE SON ASSEMBLEE GENERALE ANNUELLE DES ACTIONNAIRES

NOXXON Pharma N.V. (Euronext Growth Paris : ALNOX), société biopharmaceutique développant principalement des traitements contre le cancer en
ciblant le microenvironnement tumoral (MET), annonce aujourd’hui que l’assemblée générale annuelle
(AG) des actionnaires s’étant tenue le mardi 30 juin 2020 a nommé Dr. C. A. (Oscar) Izeboud au Conseil
de Surveillance et a approuvé l’ensemble des résolutions présentées. Des actionnaires représentant un
total de 18,55% du capital social émis et en circulation au 2 juin 2020 étaient représentés par
procuration.
« Nous sommes très heureux d'accueillir Oscar au sein du Conseil de Surveillance de NOXXON. Sa
compréhension de la médecine et sa forte expérience du financement et de l'aspect commercial du
secteur des biotechnologies constitueront un véritable atout pour la Société. Au cours de sa carrière,
alors qu'il dirigeait les activités bancaires de Kempen et NIBC dans le domaine des sciences de la vie,
Oscar a conclu avec succès plus de 100 transactions, dont 17 introductions en bourse et 15 fusions ou
acquisitions. Cette expérience, combinée à son expérience opérationnelle en biotechnologie, sera
incroyablement précieuse pour affiner et mettre en œuvre la stratégie de NOXXON », déclare Maurizio
PetitBon, Président de NOXXON Pharma.
Le mandat du Dr. Izeboud au sein du conseil de surveillance prend effet le 30 juin 2020 et durera deux
ans jusqu'à l'assemblée générale annuelle des actionnaires qui se tiendra en 2022.
Le Dr. Izeboud est le Président Directeur Général actuel de Scenic Biotech, une société de découverte
et de développement de médicaments se spécialisant dans les modificateurs génétiques, basée aux
Pays-Bas. Avant de rejoindre Scenic Biotech, le Dr. Izeboud était Directeur Général de la NIBC Bank
N.V. à Amsterdam, où il dirigeait une équipe spécialisée dans les sciences de la vie et la santé et était
en charge des activités de financement des entreprises et des marchés de capitaux, avec un focus
particulier sur les entreprises innovantes. Auparavant, il a occupé le poste de Directeur Général de
Kempen & Co., une banque d'investissement néerlandaise, dont il a développé la franchise Sciences
de la Vie et Santé et où il a joué un rôle essentiel dans de nombreuses transactions internationales dans
les secteurs des biotechnologies, des technologies médicales et de la santé. Avant sa transition vers le
secteur bancaire, le Dr. Izeboud a occupé pendant plusieurs années des postes à responsabilités au
sein de sociétés de biotechnologies, notamment Crucell NV, Specs BV et TNO Pharma.
Le Dr. Izeboud est membre non exécutif du conseil d'administration de Luciole Medical AG depuis 2019.
Il est titulaire d'un doctorat en immunopharmacologie de l'Université d'Utrecht aux Pays-Bas.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

5 days ago

Einzig Weissrussland nachlässiger als Schweiz bei COVID-19-Prävention

Article about Einzig Weissrussland nachlässiger als Schweiz bei COVID-19-Prävention

Die Schweiz war nicht nur Ende Februar bis Mitte März total unverantwortlich bzgl. COVID-19-Prävention, man hat auch nichts daraus gelernt. Die Fallzahlen steigen wieder und bei der Prävention ist nur noch Weissrussland in Europa weniger vorsichtig. 

Da schaut man mal auf das persönliche Risiko.

Selbst Schweden ist inzwischen vorsichtiger, die Datenerhebung ist weiter ungenügend.

Eine traurige Tradition in der Schweiz, dass auf die Gesundheit/Menschenrechte keine Rücksicht genommen wird, obwohl man weltweit die höchsten Gesundheitskosten - hinter den USA - hat.

Lernen ist nicht die Stärke. Man ignoriert gefliessentlich Fakten

und führt somit in den falschen Ranglisten.

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

5 days ago

Resilience Partners closes a new investment by financing the expansion of PFP Termopolimeros

 

 


Resilience Partners closes a new investment by financing the expansion of PFP Termopolimeros

 

The direct lending firm Resilience Partners Fund I S.C.A., SICAR, has closed a new investment by financing the expansion of PFP Termopolimeros S.L.

With this transaction, Resilience Partners continues its strategy of helping Spanish SMEs to finance its growth plans. Adela Mayor, CEO and founder of PFP Termopolímeros, said: “We have found an alternative which will allow us to increase our production capacity by advancing growth prospects in the coming years”. On the other hand, Agustín Pla, partner of Resilience Partners that has led the transaction added: “With this new financing Resilience Partners continues to consolidate its position as a clear alternative by helping leading companies in their industries and maintaining a wide diversification of companies in the portfolio”.

Resilience Partners continues with its solid pipeline, having also financed in February 2020 a Buy & Build process in the business services industry, and expects to close 2-3 additional investments by the end of the year. Additionally, it continues giving liquidity to investors, having made several distributions since inception, thus confirming the attractiveness of the cash component of this product.

 

About Resilience Partners

Resilience Partners specializes in helping Spanish companies with a solid track record to execute its long-term expansion plans, offering flexible financing solutions. Resilience Partners focuses on companies with EBITDA’s between EUR 3-15 M, leaders in their segment, with consolidated management teams and long-term financing needs to execute strategic plans.

Resilience Partners Fund I S.C.A., SICAR is under-investment period and parallelly is working on Resilience Partners Fund II S.C.A., SICAR maintaining the same investment strategy which forecasts to raise EUR 150-200 M among institutional investors from Europe, the United States as well as Family offices, to continue financing growth within the same target companies.

 

About PFP Termopolimeros

PFP Termopolímeros is a company specialized in the design, manufacturing, and commercialization of plastic packaging solutions mainly for the pharmaceutical industry as well as cosmetics and healthcare.

Thanks to their experience, the company has been able to stand out by offering high-quality products and adapting to their clients’ needs, including ambitious ESG projects, resource efficiency in the production process, and diversity among others. Within the company’s products offerings, PFP Termopolímeros is able to provide a specific reference only manufactured by a few companies worldwide. Their financials confirm their track record and service having grown considerably in the previous years.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

5 days ago

PZU Group leases 47000 sqm in the Skanska office building

This is the largest lease agreement in the history of the office market in Poland and the history of the Skanska Group in the world. The PZU Group has leased 47,000 sqm of office, retail, service and warehouse space, as well as 325 parking spaces in Generation Park Y – Skanska’s highest office building in CEE located in Warsaw. With this lease the building is now 98.5 percent occupied. The PZU Group will move to the new office in the second quarter of 2022. This will serve as the company’s new headquarters.


Generation Park Y is a 140-meter building crowning the Skanska office complex currently under construction near Warsaw’s Daszyńskiego Roundabout. Two years from now, the greenest skyscraper in the capital and the highest Skanska office building in the CEE region, will be filled with finance and insurance specialists from the PZU Group.

 

 

 

‘The new headquarters of the PZU Group is an investment in our employees. This is why it’s so important that Generation Park Y meets the highest standards in terms of work conditions, comfort and safety. Equally important are ecological issues and the fact that this is a facility without barriers, fully accessible by people with disabilities. Moving is an opportunity for us to create an employee-friendly space that facilitates their daily work' – says Dorota Maciej, Board Member at PZU Życie responsible for real estate at the PZU Capital Group.

 

‘Generation Park is our flagship project that reflects Skanska's approach to creating futureproof, healthy and safe working spaces. We will hand over our first high-rise office building in this part of Europe to one of the largest insurance companies in the CEE region. Green building solutions and interiors supporting employee’s well-being were extremely important factors in our discussions with the PZU Group. We have signed a contract with a company that shares our values – and that makes us even more happy’ – says Katarzyna Zawodna-Bijoch, President and CEO of Skanska commercial development business in CEE.

 

‘We are pleased that the PZU Group has decided to lease the entire Skanska high-rise building located in the heart of Warsaw's business hub. I would like to congratulate and thank everyone involved in the design, construction and business negotiations process because we have all contributed to signing this important contract. I know that the building will serve PZU employees well for many years’ – adds Arkadiusz Rudzki, Executive Vice President of Leasing & Sales at Skanska commercial development business in CEE.

 

 


The Generation Park Y tower, which will receive the address of Daszyńskiego Roundabout 4, has 38 storeys and 4 underground floors with 187 parking spots for bicycles and 325 parking spaces for cars, each equipped with sockets for charging electric vehicles. A 330 sqm green wall will be built in the lobby of the building, and thanks to the glazed facade, it will also be possible to admire the interiors from the outside. At a height of 127 meters there will be a green terrace overlooking Warsaw’s city center, which will be a great place for meetings or corporate events.

 

Generation Park Y is expected to be completed in the first quarter of 2021, and the fit out works for the PZU Group will be completed in the second quarter of 2022, which is also the date of the handover. Along with the completion of the building, the area between the office buildings of the Generation Park complex will undergo a transformation. Carefully arranged green spaces and a tree-lined square will stress the new metropolitan feel of Daszyńskiego Roundabout. A "green concrete" pavement will be created to clean the air from smog and car exhaust fumes.

 

Generation Park Y is being built in accordance with the guidelines of the most important certificates granted to office spaces. Once the work is completed, the building will apply for the LEED Platinum, Building without Barriers and the extremely demanding WELL Core & Shell certificates.

 

 

 

Skanska

 

Skanska is one of the leading development- and construction companies in Europe. Outside the Nordics, the company has operations in building construction and civil engineering in Poland, Czech Republic & Slovakia and the UK. Skanska develops commercial properties in select home markets in Poland, Czech Republic, Romania and Hungary, while residential development is active in Poland, Czech Republic and in the UK with the BoKlok concept. In 2019, Skanska had sales of SEK 33 billion and about 11,700 employees in its European operations outside the Nordics.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

7 days ago

Covid-19 accelerates digital transformation

 

 

The Covid-19 crisis caused a sharp correction in equity markets, but as we adjust to the new reality, we can observe some clear winners. Areas such as cashless payments, e-commerce, and online shopping – all of which require financial technology – are seeing accelerated growth. The crisis means the future is simply coming faster and is likely to kickstart a wider impetus to digitalize all financial services.

The rapid migration to digital technologies driven by the pandemic will continue into the recovery.
Here’s how SmartMoneyMatch can help to provide more visibility.

Should you not have an account yet, please:

As we also have the biggest event calendar dedicated to the investment industry—many of the events in the coming weeks will obviously have to be re-scheduled—we also encourage you to offer some webinars or e-conferences.

You can also list post banners. Should you be interested in a mail campaign, please contact me directly.


Martin Signer
Managing Director

 
 
 



 

 

 

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

8 days ago

The character that inspired Trump

He has the same characteristics and event bullies the same person as the current U.S. president ;-)

 

To be fair: One is properly doing the job as a comedian.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

12 days ago

Skanska implements new safety standards in office buildings and creates the new office concept

Skanska has established several rules and adapted workplaces in Central and Eastern Europe to support its tenants returning to offices. The new offer called ‘Care for Life Office Concept’ includes recommendations and consultancy regarding new hygiene and safety protocols, adjustment of existing technologies in Skanska’s buildings, and reorganization of office areas. The concept is being developed for Skanska buildings in CEE in cooperation with external experts.

Skanska commercial development business unit in CEE is an office real estate market leader that operates on ten city markets in four countries: Czech Republic, Hungary, Romania, and Poland. In March 2020, due to the coronavirus outbreak, Skanska implemented several safety precautions for its employees and business partners, as well as on project sites to ensure the safety of its people and mitigate the spread of coronavirus. This approach enabled the company to continue the construction of the projects despite the challenges caused by the outbreak. Skanska office buildings are being delivered without significant delays. This was possible thanks to efficient cooperation between the investor and general contractor within the Skanska Group.

Skanska was able to adapt to this new situation so quickly mainly due to flexibility in terms of working hours and home office rules, which already existed in the company. It would not have been possible without the extensive use of digital tools that greatly facilitate virtual meetings and everyday tasks. After months of working remotely, some employees are now coming back to offices. To provide employees with clear guidelines and information on the new set up, Skanska offices have been equipped with specially designed Visual Identifications that help follow social-distancing policies. All the pandemic related interior communication is standardized and made from sustainable materials. It includes posters and floor markings with recommendations for every area or room in the office and general rules to follow.

The global remote-working test is now becoming a return-to-the-office exercise and learning new ways of the mixed way of working both in the office and at home. It demands setting up new rules for the offices, but also a specific adaptation of our workplaces as business needs continuity. Safety and wellbeing of our employees, customers, partners, and communities are Skanska’s top priority and go hand in hand with one of our core values – Care for Life. An office has three important roles to play: integrating, culture-making, and supporting team building. We have created the new offer called ‘Care for Life Office Concept’ so offices can still fulfill their purpose in the new normal – says Katarzyna Zawodna-Bijoch, President and CEO of Skanska office business unit in CEE.

 

 

Skanska put a lot of effort into developing new and adjusting core attributes and characteristics of its office buildings, by taking advantage of WELL certification and our new technology solutions like Connected by Skanska, which enables a touchless way of moving around in an office building.

In addition to actions that have already been taken by Skanska within its own office space, knowledge and new safety standards are also shared with the company’s clients – especially those who have decided to return to the ‘new normal’. Skanska thus is launching ‘Care for Life Office Concept’ that is designed to meet the current needs of workplaces and its users. It will help identify areas that will balance safety, sustainability, and feasibility and to rethink the design of modern office spaces with regards to possible future pandemic risks. Skanska shares good practices by providing tenants with a professional advisory in the matter of office safety. With that, the company actively responds to the client’s ongoing needs or even helps to adjust existing and future fit-outs to new safety requirements. Cooperation between the owner, property managers, and tenants is crucial to organize the return to the office's process safely.

Nowadays even more attention will be paid to the issues of safety, from the quality of the work environment or even easy access to hand sanitizing solutions. Free movement around office buildings will be limited for the next months. That is why we adjusted our own offices and help tenants and clients to do so as well. For this reason, we advise on how to adapt to the new situation, how to set up the office, or even adjust the fit-out in newly delivered offices to current rules and regulations. We work closely with our own architects and an epidemiologist to provide the best-suited workplaces to our clients – comments Andrei Ivan, Sustainovation Director at Skanska commercial development unit in CEE.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

20 days ago

Neuer Schweizer Nachhaltigkeitsimmobilienindex

Edmond de Rothschild Real Estate SICAV (ERRES) als erste Komponente des Swiss Sustainable Real Estate Index (SSREI).

 Mit der Lancierung des Swiss Sustainable Real Estate Index (SSREI) wurde der Branche ein effizientes und pragmatisches Instrument zur Marktvergleichbarkeit, Beurteilung der Werthaltigkeit sowie der Transparenzsteigerung in Bezug auf die Nachhaltigkeit von Immobilienportfolios zur Verfügung gestellt. Mit dem Immobilienfonds Edmond de Rothschild Real Estate SICAV (ERRES), wird der Index nun eröffnet. Edmond de Rothschild REIM übernimmt damit eine Pionierrolle im Markt und beweist Verantwortung gegenüber ihren Investoren.

Wir freuen uns Ihnen mitteilen zu dürfen, dass die Edmond de Rothschild Real Estate SICAV (ERRES), mit der Zertifizierung ihres Gesamtportfolios, als erstes Produkt in den Swiss Sustainable Real Estate Index aufgenommen wurde. Dabei wurde das aus 75 Bestandsimmobilien bestehende Portfolio, in Bezug auf die im SSREI Portfoliobewertungstool ausformulierten Anforderungen hin bewertet und durch die Société Générale de Surveillance (SGS) verifiziert.

Der Swiss Sustainable Real Estate Index (SSREI)
Der SSREI wurde von der MV Invest mit dem Ziel lanciert, die Transparenz und Marktvergleichbarkeit von Immobilienportfolios (Immobilienfonds, Immobilienaktiengesellschaften, Anlagestiftungen und Pensionskassen) in Bezug auf deren langfristige Werthaltigkeit zu
schaffen. Die SSREI-Instrumente erlauben zudem eine Schätzung über das mögliche Verbesserungspotenzial und des damit verbundenen Investitionsbedarfs vorzunehmen. Damit sollen für die Eigentümer Anreize geschaffen werden, um ihre Immobilien entsprechend
der zunehmenden Relevanz von Nachhaltigkeitsanforderungen, zeit- und kosteneffizient auszurichten.
Der Index basiert auf einem klar definierten Anforderungsraster, der sich in Struktur und Inhalt am
Standard Nachhaltiges Bauen Schweiz (SNBS), dem offiziellen und öffentlich zugänglichen Standard von «EnergieSchweiz», orientiert. Bedingung für die Aufnahme in den SSREI ist die Verifikation («External Assurance») durch eine unabhängige Prüfstelle, um Sicherheit und Glaubwürdigkeit gegenüber dem Markt zu garantieren.

Mit der SGS wurde hierbei eine der weltweit anerkanntesten Zertifizierungsstellen mitHauptsitz in Genf beauftragt. Als exklusiven Partner des Bundesamtes für Energie (BFE) in Sachen SNBS, weist SGS ausgewiesene Erfahrung auf dem Gebiet der nachhaltigen Immobilienwirtschaft auf.

Zielgruppen
Der SSREI richtet sich insbesondere an Immobilienfonds, -Aktiengesellschaften, -Stiftungen, Versicherungen und Pensionskassen.

MV Invest
Die MV Invest AG ist eine unabhängige, auf Indirekte
Immobilienanlagen spezialisierte Beratungsgesellschaft, welche seit über 25 Jahren Immobilien­­portfolios analysiert. Dabei ist sie stets bestrebt, neue
und innovative Ansätze zu entwickeln. In diesem Zusammenhang agiert die Gesellschaft als offizieller Promoter des Swiss Sustainable Real Estate Index (SSREI). Sie ist überzeugt, hiermit einen signifikanten und nachhaltigen Mehrwert für die gesamte Industrie zu schaffen. Als Bestandteil einer ganzheitlichen Nachhaltigkeitsstrategie, so ist man überzeugt, bietet der SSREI die angestrebte Vergleichbarkeit, die gewünschte Transparenz und eine zusätzliche Visibilität, Vorteile sowohl für das anwendende Asset Management als auch für Investoren.

Edmond de Rothschild Real Estate Investment Management
Edmond de Rothschild REIM unterhält lokale Standorte in der Schweiz, in Frankreich, Grossbritannien, den Benelux-Staaten und Deutschland. Sie beschäftigt heute
mehr als 120 Immobilienfachleute in 9 Büros (7 Länder) und verwaltet ein Immobilienvermögen von mehr als 11 Milliarden Franken für eigene Immobilienanlageproduktesowie für Drittkunden. Der Fokus liegt dabei auf der Entwicklung neuer nachhaltiger Gebäude sowie auf der Renovation und energetischen Optimierung von Bestandesimmobilien.

Société Générale de Surveillance
Die SGS Société Générale de Surveillance SA mit Hauptsitz in Genf gehört zu den weltweit grössten und anerkanntesten Inspektions- und Zertifizierungsgesellschaften. Als Zertifizierungsstelle für den «SNBS 2.0Hochbau» verfügt sie in der Schweiz über ein kompetentes Expertenteam im Bereich nachhaltige Immobilienwirtschaft. Ihre Dienstleistungen im Bereich
«Green Building» sind international. Mit der eigens hierfür geschaffenen Abteilung hat sie die nötigen Strukturen geschaffen, um den globalen Markt mit den relevanten Dienstleistungen bedienen zu können.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

23 days ago

NOXXON ANNONCE L ÉMISSION DE TRANCHES D OBLIGATIONS CONVERTIBLES DANS LE CADRE DE SON ACCORD DE FINANCEMENT AVEC ATLAS

NOXXON Pharma N.V. (Euronext Growth Paris :ALNOX), société biopharmaceutique développant principalement des traitements contre le cancer ciblant le microenvironnement tumoral, annonce aujourd'hui l’émission de la troisième et de la quatrièmetranche d'obligations convertibles dans le cadre de l'accord de financement annoncé le 23 avril 2020.
En conséquence, l'investisseur, Atlas Special Opportunities, LLC, a reçu 967 Obligations Convertibles
(dont 17 Obligations Convertibles émises en lien avec les frais de transaction) d'une valeur nominale
de 1 000 euros chacune.
NOXXON tient à jour un tableau récapitulatif des Obligations Convertibles émises dans la section
"Investisseurs" de son site web.
Les caractéristiques, les modalités, les conditions et le potentiel de dilution de ce financement peuvent
être consultés dans l'Annexe du communiqué de presse publié le 23 avril 2020, également disponible
sur le site web de la société.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

24 days ago

JUST LAUNCHED: Reuters Events Transform Europe Virtual Series

Ethical Corporation by Reuters Events launches the new Reuters Events Transform Europe Virtual Series to address the big issues facing businesses as they look to deliver a new blueprint fit for a worldwide recovery post Covid-19.

Business faces significant disruption more than ever before. As it begins to adapt to the impacts and changes the Covid-19 pandemic has brought, whilst also taking stock of the ongoing climate emergency, depleting resources and biodiversity loss, it is clear that business must transform in order deliver a better future, post Covid-19.

To help navigate this landscape and address these challenges companies face, throughout the year, Reuters Events Transform Europe Virtual Series will cover three key areas pertinent to a green, clean business transformation in three instalments:

  • Transform: Sustainable Procurement & Circularity – 7-8th July 2020
  • Transform: Natural Capital & Biodiversity Week – 24-28th August 2020
  • Transform: Energy & Carbon – 28-29th September 2020

 

Over two days of live broadcast, the premiering virtual conference of the series Reuters Events Transform: Sustainable Procurement & Circularity (7-8 July), will convene leading CEOs, CPOs, CSOs and governmental representatives to share key practical solutions and tangible strategies around Covid-19 recovery, circularity, and sustainable procurement.

Some of the already confirmed expert speakers include:

  • Katharina Stenholm, Chief Procurement Officer, Danone
  • Marc Engel, Chief Supply Chain Officer, Unilever
  • Regine Lucas, Chief Procurement Officer, L'Oreal
  • Dan Bartel, Chief Procurement Officer, Schneider Electric
  • Nigel Stansfield, President EMEA, Interface
  • Kęsţutis Sadauskas, Director of Circularity & Green Growth, EU Commission
  • Sharan Burrow, General Secretary, International Trade Union Confederation
  • Marco Van Der Ree, Chief Development Officer, GRI
  • Marcela Manubens, Global VP Integrated Social Sustainability, Unilever
  • Jarkko Havas, Lead of Data and Metrics Initiative, Ellen Macarthur Foundation
  • Brent Wilton, Global Workplace Rights Director, Coca Cola
  • Kate Wylie, Global Head of Sustainability, Mars
  • Sir Ronald Cohen, Chairman, Global Social Impact Investment Steering Group

With sharing information and coming together being as important as ever during these difficult times, all the offerings in the Reuters Events Transform Europe Series are free to attend. One registration allows access to all the live and on-demand material of all the events on our online platform.

Liam Dowd, managing director at Ethical Corporation by Reuters Events, states “we excited to launch this new event series at a critical juncture for business. The 20’s have been marked as the decade of action. Across our three virtual events, our ambition is to provide actionable ideas and insights as to how business can help deliver a resilience, sustainable, and inclusive recovery.”

Ethical Corporation by Reuters Events is to help businesses around the globe do the right thing by their customers and the world. We believe this is not only how to guarantee a future for all, but makes good business sense. We serve sustainability, communications, supply chain, and ESG with topical and insightful business intelligence and meeting places.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

24 days ago

Join Secretary Steven Mnuchin and David Solomon at Bloomberg Invest Global

 

 

 


Bloomberg invites you to join us for
Bloomberg Invest Global. Taking place on June 22-24, this global virtual event brings you daily conversations from Hong Kong, Dubai, London, and New York.

Join us live or on-demand as we sit down with the biggest names in finance economics and investing including The Honorable Steven Mnuchin, William Ackman, Stephen Schwarzman, and David Solomon. We’ll be discussing what the economic recovery will look like and when will it begin, the length that central banks will need to go to mitigate the growing socio-economic impacts of this pandemic and, where and when investors should put their money to work.
RSVP
View the entire speaker lineup and agenda

Speakers Include

William Ackman, CEO and Portfolio Manager, Pershing Square Management
Carson Block, Found & CEO, Muddy Waters Research
Jim Chanos, President and Founder, Kynikos Associates
Heenam Choi, CEO, Korea Investment Corp
Ángel Gurría, Secretary-General, OECD
Lim Chow Kiat, CEO, GIC
The Honorable Steven Mnuchin, Secretary, U.S. Treasury         
Sheila Patel, Chairman, Goldman Sachs Asset Management
Yves Perrier, Chief Executive Officer, Amundi
Bob Prince, Co-Chief Investment Officer, Bridgewater Associates
Manny Roman, CEO, PIMCO
David Rubenstein, Co-Founder and Co-Executive Chairman, The Carlyle Group
Stephen A. Schwarzman, Chairman, CEO and Co-Founder, Blackstone
David Solomon, Chairman and CEO, The Goldman Sachs Group, Inc.
Jessica Tan, Group Co-CEO, Ping An Insurance Group
 
 
 

 

 

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

25 days ago

Matching capital needs

As simulation studies illustrate, the health impact of COVID-19 is still far from over even if in most places the peak of the first wave of the pandemic has passed, as these interactive charts with current data show.

Transmission mitigation using social distancing, hand hygiene, and protective gear such as masks, will remain very important.

A lot of businesses face liquidity issues, and need some resilience in form of e.g., equity or debt/bridge-financing from investors or bankingservice providers, while at the same time some capital allocators inefficiently hold a lot of dry powder. 

It is the purpose of SmartMoneyMatch to contribute to a well-functioning market especially in these extraordinary times by bringing the main stakeholders like investors, service providers, and organizations looking for capital for their offers together.

To make the most use of it, do the following (at no charge):

Of course, it's also recommended to participate in (online) events/webinars—or publish your own—network with professionals from the organizations you want to connect with, list vacancies on the job board, publish your article in  the blog and have a banner ad (which is pay-per-click, so you only pay for realized clicks and can set a maximum budget).

Kind regards,

Martin Signer
Managing Director

P.S. 

 

Be seen. Be heard. Be remembered.

We offer visibility to our network of 450,000+ people:


To find out more, get in touch with
Martin.Signer@SmartMoneyMatch.com +41 43 333 10 38.

 
 
 

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

26 days ago

War der Lock-down notwendig?

Article about War der Lock-down notwendig?

Wie die wissenschaftliche Publikation im Nature zeigt, war das Herunterfahren der Wirtschaft eine erfolgreiche und wirksame Methode um die Gesundheit/Leben von grossen Bevölkerungsteilen zu schützen.

V. a. in Europa und Nordamerika wie bspw. der Schweiz and Schweden würden die Massnahmen wesentlich zu spät eingeführt.

Siehe dazu auch die Übersicht

Es lohnt sich auch die verschiedenen Daten mit den Massnahmen zu vergleichn.

Nicht ganz erstaunlicherweise sind auch die Staaten, welche eine hohe Doppelmoral aufweisen, vom Virus besonders stark betroffen. Die Behördenaussagen waren - und sind auch immer noch - teilweise wiedersprüchlich.

Lernen wir für andere Herausforderungen etwas? Wohl nicht.

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

30 days ago

New York roadshow

New York roadshow organized by 4Finance

Organizer
Martin Signer
Date
Jun 25, 2020
Description
Roadshow in New York

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

1 month ago

Vaccine with or without me?

Article about Vaccine with or without me?

People are eagerly waiting for an efficient vaccine against COVID-19. The current development state is in this COVID-19 vaccine tracker available.

Obviously, vaccines are associated with benefits/risks that cause a lot of controversies.

Some decision-making tool is here.

Some vaccines seem to have - especially live attenuated vaccines -  some beneficial non-specific effects.

The most prominent ones are:

Obviously, people are also rightfully concerned about the adverse side-effects of vaccines. 

In contrast, five non-live vaccines researchers studied: DTP vaccine, pentavalent vaccine, inactivated polio vaccine, H1N1 influenza vaccine, and hepatitis B vaccine. These all increase the overall mortality rate, especially among girls, even if they protect against the target diseases.

From the decision theory, the decision in favor of a vaccine should be if the benefits (mainly probability multiplied by severeness of not getting the infection, positive side effects multiplied) outweigh the costs (mainly probability of negative side/vaccination damages effects multiplied by severeness). 

As pointed out, lots of data for good decision making are missing that may lead to sub-optimal decisions (in favor of or against a certain vaccination).

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

1 month ago

Onda Group to Benefit from Eco-Bonus provided by Italian State

Onda Group to Benefit from Eco-Bonus provided by Italian State; Potential Market for Onda Group 1.200.000.000 (1,2 Billion)

 
 
 

Energy Company Benefiting from Anticipated Human Flight to Mediterranean Regions by Northern Europeans.

Onda Group, a preeminent supplier of energy to Southern Italian businesses, homes, and local utilities announces that it is ready to supply cheaper energy for restarting the economic engine of the region by supplying lower-cost energy alternatives for its customers. With the sharp drop in oil & gas prices and the huge disruption of the Italian economy, Onda plans to supply the region with cheaper energy alternatives that have not been seen in prices for the last 30 years. 
 
Cheaper energy means that the regions of Sicily, Sardegna, and the Southern Italian mainland should see a resurgence of economic activity partly due to lower energy costs provided by Onda. Onda will bring to the market a technological “Killer Application” able to collect new clients and keep them forever. A smart meter provides the consumption in €, of a single device (lamps, fridges, ovens, etc). Its name is Efficento, and it is a unique technology in the European market.

As Italy recovers from the Covid-19 pandemic, Onda is poised to help jump-start this economy by providing low-cost energy products to its customer base, and the company plans to rapidly expand and increase its market share in this region. The company CEO, Luigi Martines, states “Onda will make all efforts to sell its customers energy at low prices in order to get the Italian economy moving again. It is our responsibility as energy suppliers, to pass savings on to our customers for a quick and sustainable recovery. We expect to increase overall sales and expand our services in Sicily, Sardegna, and Southern Italy to make Onda a decisive player in the energy markets in the near future.”

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Todos Medical Announces First Commercial Sale of COVID-19 Antibody Tests

 
 
 

Todos Medical Announces First Commercial Sale of COVID-19 Antibody Tests

  •  Sub-distributor has a network of state and local government clients seeking testing solutions
  •  Return to Church program being initiated in Orlando, Fla. area

Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer’s disease, today announced its first commercial sale of COVID-19 tests.  The sale was made via a sub-distribution agreement with a U.S.-based medical distribution company with clients in state and local governments throughout the Southeastern United States who are seeking comprehensive testing solutions for Return-to-Work programs. Todos’ sub-distributor’s first sale was for rapid IgM/IgG fingerprick antibody test kits that will be deployed over Memorial Day weekend for the first of several Return to Church programs being planned. Todos’ sub-distributor’s church network covers over 84,000 Christian church congregations reaching over 28 million Americans. 

“This sub-distribution agreement gives Todos’ U.S. distribution division access to a network of state and local governments, as well as Christian churches, and other communities of faith, that are for the first time pursuing COVID-19 testing services as they seek to responsibly reopen their congregations,” said Gerald E. Commissiong, President & CEO of Todos Medical. “We provide organizations and their lab partners with access to a comprehensive, steady supply of bundled, high-quality, FDA-compliant PCR, and antibody testing solutions that address their needs as they implement COVID-19 testing programs. As private organizations begin to take control of their COVID-19 testing, Todos plans to be a solutions provider for both organizations and labs seeking to more efficiently administer COVID testing in the United States.”

 
 
 
 

About Todos Medical Ltd.

Headquartered in Rehovot, Israel, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the second quarter of 2020.

Through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. (OTC: AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the second quarter of 2020.

Todos recently entered into distribution agreements with China-based companies to distribute certain novel coronavirus (COVID-19) test kits. The Company has entered into distribution agreements covering the U.S. and Israel with Gibraltar Brothers & Associates, LLC, a U.S.-based subsidiary of Shanghai Liangrun Biomedicine Technology Co. (Shanghai), for its proprietary colloidal gold immunochromatography (Colloidal Gold) point-of-care IgM/IgM-based antibody test kits, and with 3DMedicine Science & Technology Co (3DMed), a China-based cancer precision medicine company, for distribution in the U.S. and Israel of its ANDiS® SARS-CoV-2 Detection Kit (COVID), ANDiS® SARS-CoV-2  & Influenza A/B Detection Kit (COVID/Flu) and its proprietary ANDiS®350 3DMed Automated Solution countertop real-time PCR machine (3D Machine). Todos has formed Corona Diagnostics, LLC, a joint venture with Emerald Organic Products, Inc.  (OTC: EMOR), to support the commercialization of its COVID-19 testing paradigm.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Omnia Wellness Is Prepared for Re-Opening of the Economy

Omnia Wellness ramps up its marketing activity as Medical Centers, Fitness Clubs, Corporate Offices, Salons, and Spas reopen in the US

 
 
 

Omnia Wellness is commercializing a new and innovative massage therapy approach with a unique automated massage bed called SolaJet that requires no personnel or a massage therapist. More than massage, SolaJet’s Dry-Hydrotherapy technology provides deep tissue suppression, therapeutic heat and a flushing full-body “wave” combining 3 therapies in 1. Treatments deliver the similar feeling of an hour-long traditional massage in as little as 15 minutes at an affordable price point for the consumer without the need of human hands.  Omnia Wellness is redefining and expanding the $45 billion global massage industry by delivering better, more efficient and a more customer-friendly massage experience.

Please find attached the Omnia Executive Summary and an Evergreen Research brief on Omnia Wellness, which describes the company’s target market, the SolaJet massage bed function and its benefits, and projected revenues. 

  • The SolaJet Dry-Hydrotherapy System is a massage bed that comprises a water-filled vessel where a powerful motor delivers all the benefits of conventional touch massage by pumping highly pressurized jets of water into specific parts of the impermeable barrier on a targeted basis
  • SolaJet’s hardware features are a strong water-proof flexible shell, a 4 horsepower motor and high pressure water jets which dispense from a rail mounted feeder that travels the full length of the body
  • SolaJet delivers a therapeutic massage through its flushing wave action and has heat therapy controls for the end-customer’s treatment requirements giving deep tissue massage, vibration, heat therapy and a full body flushing wave
  • SolaJet is operated through a touch screen tablet mounted to the side of the bed or user-determined smartphone app, so there is no need for human interaction with either a consultation with or touch from a designated on-premise practitioner

On April 21, 2020,  Omnia Wellness, Inc., trading under (OTC: OMWS), announced the entering into a Share Exchange and Reorganization Agreement with a Denver-based privately held company Bed Therapies, Inc. (now Omnia Wellness Corporation), pursuant to the Exchange Agreement 8K below.  The completion of the Exchange Agreement is expected by the end of June.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Baustaatssekretärin Bohle übernimmt Schirmherrschaft für den Sonderpreis Bezahlbares Bauen

„Nachhaltig, innovativ und zugleich bezahlbar bauen: Angesichts der politischen Rahmenbedingungen stehen Projektentwickler heute vor der Quadratur des Kreises. Zusätzlich erschweren die Folgen der Corona-Pandemie die Fertigstellung von neuen Projekten. Deshalb freuen wir uns sehr, dass Anne Katrin Bohle, Staatssekretärin im Bundesministerium des Innern, für Bau und Heimat die Schirmherrschaft für den „FIABCI/BFW Sonderpreis für bezahlbares Bauen“ übernommen hat!” Das gab Andreas Ibel, BFW-Präsident und Mitglied der Jury, heute in Berlin bekannt.

„Der von FIABCI und dem BFW ausgelobte Prix d’ Excellence Germany zeichnet herausragende Projekte aus, die vorbildhaft verschiedenste Ansprüche an moderne und nachhaltige Gebäude vereinen“, honoriert Anne Katrin Bohle, Staatssekretärin im Bundesbauministerium. „Gerade in Zeiten der Corona-Pandemie zeigt sich die mittelständische Immobilienwirtschaft als ein starkes Rückgrat in der Wertschöpfungskette der Bundesrepublik. Gerne übernehme ich daher erneut die Schirmherrschaft für den „Sonderpreis für bezahlbares Bauen“ und freue mich auf zahlreiche Projekte die zur Nachahmung anregen.“

„Neben der Bezahlbarkeit sind innovatives Denken und Bauen eine der größten Herausforderungen für Projektentwickler“, sagt Michael Heming, Präsident FIABCI Deutschland. „Deshalb loben wir einen weiteren Preis, den Innovationspreis aus: Denn wir wollen zu innovativem nachhaltigem Bauen inspirieren und die Synergien zwischen Bauwirtschaft und Baukultur fördern!“

Zum ersten Mal in der Geschichte des FIABCI Prix d´ Excellence Germany wird der Sonderpreis „Langer Atem“ ausgelobt – „mit einem Augenzwinkern“, so Heming und Ibel: „Allen Projektentwicklern ist gemein, dass sie mit Abstimmungsproblemen, langwierigen Prozessen und baurechtlichen Hindernissen zu kämpfen haben. Deshalb vergeben wir den Preis für den Projektentwickler, der mit den skurrilsten Problemen zu kämpfen hatte, um sein Projekt fertig zu stellen!“

Für den FIABCI Prix d´Excellence Germany 2020 sind alle Immobilienprojekte zugelassen, deren Fertigstellung zwischen dem 1. Januar 2018 und 31. Dezember 2020 erfolgt ist. Die Bewerbungen können bis zum 15. Juni eingereicht werden. Die Gewinner des Wettbewerbs werden am 13. November im Rahmen einer feierlichen Gala im Berliner ewerk gekürt.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Subsidiary of the Solution of ViralClear to Treat Adult Patients with Advanced COVID-19

FDA Clears the Investigational New Drug Application to Enable the Phase II Trial of ViralClear’s Merimepodib, Oral Solution to Treat Adult Patients with Advanced COVID-19

 

Todos Medical Ltd. (TOMDF), a pre-commercial stage in vitrodiagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, announces that its President and Chief Executive Officer Gerald E. Commissiong has provided the following corporate update on the Company’s ongoing initiatives, including progress with its novel coronavirus (COVID-19) joint venture Corona Diagnostics, LLC,   the ongoing breast cancer commercialization trial with its proprietary blood spectroscopy platform, and the pending acquisition of its Alzheimer’s disease joint venture Breakthrough Diagnostics, Inc.

 

 

  • Phase II clinical trial expected to be conducted at multiple centers in the United States, including three Mayo Clinic sites under the leadership of Andrew D. Badley, M.D., Enterprise Chair of COVID-19 Task Force
  • A randomized, double-blind, placebo-controlled clinical trial to be conducted in adults with COVID-19 who are hospitalized and either require supplemental oxygen or are on non-invasive ventilation or high flow oxygen devices

 BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority-owned subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced that the U.S. Food and Drug Administration (FDA) has completed its review of ViralClear’s Investigational New Drug (IND) application. The FDA informed ViralClear that it may proceed with a proposed phase II study of merimepodib oral solution in adults with COVID-19 who are hospitalized and either require supplemental oxygen or are on non-invasive ventilation or high flow oxygen devices.

This study will be a randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of merimepodib as an orally administered treatment. The trial will occur in hospitalized patients who have confirmed infection with SARS-CoV-2 and require supplemental oxygen.

“I’m very pleased to be involved in this planned Phase II study of merimepodib for the treatment of patients with COVID-19 disease,” said Andrew D. Badley, M.D., Professor and Chair of Department of Molecular Medicine and the Enterprise Chair of COVID-19 Task Force. “We are grateful to the FDA for their prompt response in helping accelerate opportunities to find treatments for the novel coronavirus. We plan to begin enrollment of this trial as soon as practicable given the importance of finding solutions to this pandemic.”

“FDA clearance for our proposed phase II trial to proceed is an important step for the development of merimepodib,” commented Jerome B. Zeldis, M.D., Ph.D, Executive Chair, co-founder and acting Chief Medical Officer of ViralClear Pharmaceuticals, Inc. “We intend to conduct Phase II evaluations of our drug both in the hospital and outpatient settings as part of our clinical development plan.”

“We thank the Mayo Clinic for collaborating with us to conduct the trials under the leadership of Professor Badley,” said Nick Spring, Chief Executive Officer of ViralClear Pharmaceuticals, Inc. “Of the therapies that are currently being evaluated as treatments and can be available in the short term, we believe that a broad-spectrum antiviral that is orally administered and widely available could be very helpful in addressing the COVID-19 pandemic. We further believe it can play a pivotal role in helping manage this type of public health crisis.”

 

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring, and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

About Merimepodib (MMPD)
Merimepodib, a broad-spectrum anti-viral candidate, that demonstrates strong activity against COVID-19 in cell cultures in laboratory testing and additional antiviral studies are underway.  Merimepodib was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with 12 clinical trials conducted (including 315 chronic hepatitis C patients, 24 psoriasis patients, and 98 healthy volunteers) and an extensive preclinical safety package completed.

A manuscript titled, “The IMPDH inhibitor merimepodib provided in combination with the adenosine analog remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro”, was submitted to an online peer-reviewed life sciences journal. This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang, and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding author. This article highlights pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch.

About ViralClear
BioSig’s subsidiary ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical to treat COVID-19. Merimepodib is intended to be orally administered and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against COVID-19 in cell cultures. Merimepodib has been previously studied in 12 clinical trials, including 5 in patients with hepatitis C (1 Phase 1b, 1 Phase 2, 2 Phase 2a, and 1 Phase 2b), 1 in patients with psoriasis (Phase 2), and six in healthy volunteers (Phase I). 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Reckless arms exporters to Saudi Arabia worst hit by COVID-19

Reckless arms exporters like the US and the UK - big arms exporters to Saudi Arabia - are among the worst-hit countries from COVID-19. Is this a surprise?

Infographic: Who Exports Arms to Saudi Arabia? | StatistaAs visible, these are almost the same countries that are proportionally hardest-hit with COVID-19

Infographic: The World's Largest Arms Suppliers | Statista 

No.

As already mentioned earlier, arms exports are usually done with barter trades and they are typically aligned with - at least morally - corrupt governments that don't value the well-being of others.

As an example, the defense minister of Switzerland - a country with huge war material exports - only concentrated on the barter agreement for a new military airplane instead of pandemic prevention. This lead - among other reasons - to Switzerland becoming one of the worst-hit countries from COVID-19.

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Wo verliert man gute Lebensjahre?

Article about Wo verliert man gute Lebensjahre?


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

By looking at the data it would make sense to tax beef and lamb meet more instead of VAT

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Umweltpolitik mit höherer Besteuerung von Rinds- und Lammfleisch und tieferer Mehrwertsteuer

Article about Umweltpolitik mit höherer Besteuerung von Rinds- und Lammfleisch und tieferer Mehrwertsteuer

Rind- und Lammfleisch sind die Proteinquellen, welche am meisten Treibhausgase emittieren und sollten daher höher besteuert werden (dafür sollte die asoziale Mehrwertsteuer reduziert/abgeschafft werden).

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Merimepodib and Remdesivir Against SARS-CoV-2

ViralClear Publishes in F1000 Research In Vitro Data Demonstrating Synergy between Merimepodib and Remdesivir Against SARS-CoV-2, the Cause of COVID-19

 
 

Todos Medical Ltd. (TOMDF), a pre-commercial stage in vitrodiagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, announces that its President and Chief Executive Officer Gerald E. Commissiong has provided the following corporate update on the Company’s ongoing initiatives, including progress with its novel coronavirus (COVID-19) joint venture Corona Diagnostics, LLC,   the ongoing breast cancer commercialization trial with its proprietary blood spectroscopy platform, and the pending acquisition of its Alzheimer’s disease joint venture Breakthrough Diagnostics.

 

Westport, CT, May 14, 2020 (GLOBE NEWSWIRE) --

  • Merimepodib in combination with remdesivir decreases viral production of SARS-CoV-2 to undetectable levels in pre-clinical testing.  Even at low concentrations of both drugs significant reduction in viral production occurs.
  • Article highlights recent work done in laboratory studies of COVID-19 with merimepodib at the Galveston National Laboratory at The University of Texas Medical Branch

BioSig Technologies, Inc. (Nasdaq: BSGM) today announced that an article titled, The IMPDH inhibitor merimepodib provided in combination with the adenosine analog remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro” was published by F1000 Research, an online peer-reviewed life sciences journal publishing program in biology and medicine, while it is undergoing peer review.

This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, Timothy Wanninger, John T. Manning, Cheng Huang, and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding author. The link to the manuscript is https://f1000research.com/articles/9-361/v1.

The article highlights pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch. 

“The results of these laboratory investigations have strongly influenced our plans for the initial clinical trials of merimepodib. We have experimental evidence that merimepodib is active as monotherapy and in combination with remdesivir,” commented Jerome Zeldis, M.D., Ph.D.,  Executive Chair and Co-Founder of ViralClear Pharmaceuticals, Inc. “Our first proposed COVID-19 trial is expected to be conducted in hospitalized patients who require supplemental oxygen and receive remdesivir as part of their standard of care.  Patients will be randomized to either placebo or merimepodib. In this manner, the potential synergy between merimepodib and remdesivir may be evaluated in the clinical setting.  An additional trial in the outpatient setting with just merimepodib is proposed to follow the initiation of the first trial.”

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring, and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

About ViralClear
BioSig’s subsidiary ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical to treat advanced COVID-19.

Merimepodib is a broad-spectrum antiviral agent that has demonstrated strong activity against the SARS-CoV-2 virus in cell cultures in laboratory testing. ViralClear plans to initiate a multi-center, phase 2, randomized, double-blind, placebo-controlled study of the efficacy and safety of merimepodib administered orally three times a day for 10 days in combination with remdesivir administered by intravenous infusion once a day for 5 or up to 10 days in adult patients with advanced COVID-19 upon FDA clearance to proceed. Merimepodib has been studied in twelve clinical trials prior to this planned study, including five trials in patients with hepatitis C (one phase 1b, one phase 2, two-phase 2a, and one phase 2b), one trial in patients with psoriasis (phase 2), and seven trials in healthy volunteers (phase 1). 

Remdesivir is an adenosine analog that displays broad-spectrum antiviral activity against RNA viruses and has been developed by Gilead Pharmaceuticals for the treatment of Ebola. On May 1, 2020, remdesivir received an FDA Emergency Use Authorization to treat COVID-19 in adults and children hospitalized with severe disease.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Bauträger zunehmend von Folgen der Corona-Pandemie betroffen

„Die Auswirkungen der Corona-Pandemie stellen die mittelständische Immobilienwirtschaft vor immer größere Herausforderungen. Unsere neue Mitgliederumfrage zeigt: Neben den Bestandshaltern sind nun auch die Bauträger zunehmend betroffen“, sagte Andreas Ibel, Präsident des BFW Bun-desverbandes Freier Immobilien- und Wohnungsunternehmen, heute in Berlin. Hier präsentierte Ibel die neue Umfrage unter den mittelständischen BFW-Mitgliedsunternehmen, die 50 Prozent der Wohnungs- und 30 Prozent der Gewerbeimmobilien bauen und 14 Prozent des gesamten Mietwoh-nungsbestandes verwalten.

In der Umfrage geben 75 Prozent der befragten Immobilienunternehmen an, dass ihr Geschäftsbetrieb durch die Corona-Krise beeinträchtigt ist. Dabei rechnen 65 Prozent der Bestandshalter mit Beeinträchtigungen. Bei den Bauträgern und Projektentwicklern sind es sogar 79 Prozent.

Auswirkungen auf der Baustelle

Die größten Probleme für die Bauträger sind neben der Vermarktung (38 Prozent) die Planung und Genehmigung neuer Projekte (37 Prozent). So berichten vier Fünftel der Bauträger, dass die Erteilung von Baugenehmigungen, die Schaffung von Planungsrecht und die Bauleitplanung auf kommunaler Ebene noch länger dauern als ohnehin üblich. Auch beim Betrieb und der Organisation von Baustellen kommt es laut 21 Prozent zu Schwierigkeiten, etwa durch das Ausbleiben von Subunternehmen oder durch die erforderlichen Sicherheitsmaßnahmen. Darüber hinaus berichten 38 Prozent der Bauträger von verzögerten oder unterbrochenen Lieferketten.

Drei Viertel der Bauträger rechnen mit Umsatzeinbußen

Entsprechend verhalten äußern sich die Bauträger beim Blick in die Zukunft: So gehen 61 Prozent davon aus, dass die Anzahl der beantragten Baugenehmigungen in diesem Jahr sinken wird. 71 Prozent der Befragten rechnen damit, dass sich geplante Baubeginne um mehrere Monate verschieben werden. Für 63 Prozent zeichnet sich schon jetzt ab, dass es auch bei der Fertigstellung von Projekten zu mehrmonatigen Verzögerungen kommen wird. Die Folge: Drei Viertel der Bauträger rechnen damit, dass sich die Pandemie negativ auf ihren Umsatz auswirken wird. 28 Prozent geben an, dass ihr Umsatz voraussichtlich um mehr als zwanzig Prozent zurück gehen wird. Dennoch nehmen bislang nur 13 Prozent der befragten Unternehmen staatliche Hilfen in Anspruch. Lediglich 17 Prozent schicken Mitarbeitende in Kurzarbeit.

Jetzt sind die Kommunen gefragt!

„Die Immobilienunternehmen spielt eine Schlüsselrolle, wenn es darum geht, unsere Wirtschaft nach dem Lock-Down wieder anzukurbeln. Auch das Problem der Wohnungsknappheit wird sich weiter verschärfen, wenn wir hier nicht gegensteuern“, sagte Ibel und erklärte: „Als Mittelstand haben wir bislang staatliche Hilfen für unsere Kunden und Mieter, nicht aber für unsere Unternehmen gefordert. Deshalb ist es jetzt dringlicher, dass Verfahren auf kommunaler Ebene weiter vereinfacht, beschleunigt und digitalisiert werden, um einen Einbruch beim Neubau abzuwenden. Mit dem Planungsbeschleuni-gungsgesetz hat der Bund hierfür die Rahmenbedingungen neu justiert. Jetzt sind die Kommunen gefragt!“

Die Umfrage wurde vom 29. April bis zum 6. Mai erhoben. Die detaillierten Umfrageergebnisse können Sie hier einsehen.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Zapaygo: The contactless payment platform

 

 
 

Imagine being able to order your food and drinks as you are approaching a venue, not waiting in lines to order, pay and have your order prepared. Everything is just there ready for you to collect. Ordering from your seat and not having to try and get a server’s attention or leave people and stand at a bar waiting while you miss that vital business discussion, joke or sporting moment! You don’t even have to wait for the bill when you’re finished. What’s more, you do not have to handle money, touch card machines or ATM’s, you don’t have to queue and/or stand in confined spaces waiting for your order to be prepared (all mitigating the risk of spreading disease). Not only do you save time and stay safe, but you also earn rewards and cashback.
You can do all this from a free, user-friendly app that allows you to pre-order from your favourite places.
Pre-order > Save Time > Earn Rewards
and “STAY SAFE”


What Zapaygo has:
  • Great contract with MSL Solutions to ensure millions of users are quickly onboarded, integrated into over 60% of the UK’s high profile Sports and Concert venues EPOS systems.
  • MVP ready to go.
  • Routes to tens of thousands of bars and pubs via senior teams contacts
  • Partnerships (signed or teed up) with Monek / Datam / Rimilia / Paycasso / Interactions / Rapyd / Global Reach / Push Technology / PayPal /Amex / Birmingham 2020 / VODXS/ Dubai World Expo 2021 / Tata Consultancy services blockchain rewards program / Rypplzz
  • Endless launch opportunities in the UK due to team contacts (too many to mention).
  • A perfect storm business opportunity now due to COVID-19, businesses need to reopen.
  • Great team with all the contacts and experience needed.
  • Zapaygo also has its own delivery software ready to roll out, www.zapaygodelivered.com
  • Lots of lessons learned and heavy lifting completed
  • See how it works 
  • There is also an IEO starting at 09:00 local time in Singapore on Sunday 17th May please visit www.wenxpro.com to sign up ready.
Invest
 
 



Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

FLUXUS introduces an AI-enabled Digital Toolkit for Affordable Housing Development

FluxHouse™ Generative, an AI-enabled Digital Toolkit for Affordable Housing Development

Fluxus is pleased to introduce FluxHouse™ Generative, a state-of-the-art AI-enabled digital toolkit for developers and governments to design, assess, and deploy affordable housing projects.

“While affordable housing delivery is increasingly impacted by the current situation with supply chain interruptions, construction slowdowns, and funding shortages, we are also witnessing the acceleration of digital transformation in construction and real estate sectors that are ripe for innovation for a long time. Embracing tools and platforms for digitalization will help developers and governments to better manage risk, enable collaborative workflow globally, plan for sustainability, and ultimately help to strengthen the ability of communities to meet the affordable housing needs.” – Fanyu Lin, CEO of Fluxus.

In FluxHouse™ Generative, algorithms are developed to automate the assembly of the FluxSystem’s 9 components to form varying massings and layouts which directly respond to define physical and environmental conditions. The tool adapts typical footprints, using GIS-data, to optimize volumes to achieve the highest yield of units and drive value. Customizable floor plans are spacious and aesthetic with liberal use of natural lighting. Passive design principles are incorporated with IoT solutions to reduce energy consumption.

Committed to offering an energy-efficient and affordable housing solution for quality of living through leveraging networks of global partners and digitalization of construction, Fluxus is looking forward to engaging with more government, developer, housing provider, funder and other interested parties to roll out development projects while creating industry-wide resilience in a post-Covid-19 world.

 

About Fluxus

Founded in 2013 in New York City, Fluxus LLC is a privately held construction/architecture technology company, committed to delivering affordable housing through a prefab building platform that leverages networks of global partners and innovations in smart city technologies, green building materials, intelligent design, industrialization and digitalization of construction.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

How is smoking and COVID-19 related?

Article about How is smoking and COVID-19 related?

The WHO is not very clear in its statement.

There is a study running on whether nicotine patches might help.

Below also some data to compare.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

ETF Stream aquires AltFi

 

According to a newsletter from AltFi, they are joining ETF Stream, as part of an expansion plan for both publications in Europe.

Over the last 18 months, AltFi has seen a huge growth in our readership along with an expansion of the events and research business.

The two brands will remain editorially independent and separate from each other but will benefit from expanded events, marketing, and sales team.

They aim to keep writing the cutting-edge fintech and alternative finance stories that matter to you, and covering the most exciting and original innovators in financial services and banking.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Genprex is 39%up on premarket on Oncoprex IP deal

  • Nano cap Genprex (NASDAQ:GNPX) jumps 39% premarket on robust volume in reaction to its agreement with MD Anderson Cancer Center for exclusive global rights to a portfolio of 16 patent applications and related technology for the treatment of cancer using TUSC2 gene therapy Oncoprex combined with other immunotherapies, including PD-1/L1 inhibitors, PDL2 inhibitors, anti-CTLA-4 antibodies and/or anti-KIR antibodies.
  • The company plans to file an IND for a clinical trial evaluating the combination of Oncoprex and Merck's (NYSE:MRK) Keytruda (pembrolizumab) in patients with non-small cell lung cancer.
  • It says this therapeutic approach is distinctly different from combining Oncoprex with targeted therapies like AstraZeneca's Tagrisso (osimertinib).

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

The HSC Fund purchases a modern and profitable multi-tenant property close to Geneva airport

The Helvetica Swiss Commercial Fund (HSC Fund) acquires a modern, mixed-use commercial property in Versoix in the Canton of Geneva. The market value of the property amounts to CHF 31.14 million. The rental income from the property derives from 8 tenants and is largely secured over the next 10 years by the seller with a guarantee structure established over different levels.

 

The HSC Fund signed a purchase agreement for a modern, mixed-use commercial property in Versoix/GE with a privately held company. The property is situated in a well-developed and economically intensive location close to the airport Geneva. The property has a rentable surface of around 7,300 square meters and generates an income of ca. CHF 1.43 million per year with 8 tenants. The acquired property measures around 12,750 square meters.

The property is mostly rented out on a long-term basis. A large part of the rental income is collateralized for the long-term over a contractually protected transaction structure. This transaction structure ensures that the HSC Fund accrues the full target rental income regardless of the future occupancy rate. Of the contractually agreed rental income of around CHF 14.3 million over the next 10 years, over CHF 7.3 million are guaranteed by a combination of temporary retention of the purchasing price and additional ten-year bank guarantees. In addition to the usual tenant’s security deposits, the seller’s parent company secures all of the seller’s obligations over the duration of 10 years. The seller will also oversee the management of the building in the future.

The multi-tenant property at a very attractive location

The property was built in 2013. The average rent (excl. parking) amounts to around CHF 180 per square meter and year. In addition to the very attractive transaction structure, the HSC fund also benefits from the fact that it is only responsible for the maintenance of the constructive elements of the new property. All other investments, also investments in rental spaces, and all auxiliary costs are covered by the property manager. As such the actual return which lies just under 5% on the invested capital, is further improved be a very low “double-net cost structure”. The return on the market value lies at the time of purchase at around 4.6%.

Purchase agreement notarized, benefits and risks transferred retroactively as of 1 May 2020

The purchase agreement was notarized in Geneva on 30 April 2020 in compliance with the social distancing requirements of the Federal Council. In the Canton of Geneva, the contract is subject to a statutory right of first refusal by the FTI (Foundation pour les terrains Industriels). The contracting parties do not expect the FTI to exercise this right of first refusal. Subject to the FTI's right of first refusal, the transfer of benefits and risks will take place retroactively as of 1 May 2020.

"With the acquisition of this property and the transaction structure, we can ideally meet the current needs of our investors: Our investors not only benefit from an attractive return but also enjoy the greatest possible cash flow security due to the extensive rent guarantees deposited to secure the business as well as the staggered payment of the purchase price," says Frederic Königsegg, Chief Investment Officer.

HSC Fund expands its portfolio into the French-speaking part of Switzerland with this acquisition and continues its long-term growth strategy prudently and in the interest of its investors.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Novacyt mises à jour sur le test pour le coronavirus et date de publication des résultats

Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, fait le point sur son test d'amplification en chaîne par polymérase (PCR) pour le COVID-19 mis au point par Primerdesign, la division de diagnostic moléculaire du Groupe basée au Royaume-Uni.

Ventes

En date du 28 avril 2020, Primerdesign a vendu, reçu des commandes ou été sélectionné pour livrer pour plus de 90 millions de livres sterling (103 millions d'euros) de tests pour le COVID-19. Ce chiffre comprend le montant minimum de commandes de tests prévu par le contrat d'approvisionnement récemment signé avec le Ministère britannique de la Santé et des Affaires Sociales et la demande minimum prévue dans le cadre des collaborations avec AstraZeneca, GSK et l'université de Cambridge.

Novacyt fournit désormais son test COVID-19 dans plus de 100 pays et des approbations pour ce test ont été récemment reçues de la Malaisie et de l'Équateur. Le Groupe continue d’accroitre son niveau de vente sur le marché américain et évalue les options possibles pour étendre sa présence sur cet important marché.

Capacité de production

Le 15 avril 2020, Novacyt a annoncé une stratégie visant à augmenter la capacité de production à environ huit millions de tests par mois. Le Groupe est en bonne voie pour la réaliser et prévoit d'atteindre au moins ce niveau de production en juin 2020. En outre, Novacyt a signé des contrats de sous-traitance avec deux autres fabricants basés au Royaume-Uni. Novacyt dispose ainsi d'un total de six fabricants en sous-traitance en plus de ses propres sites de production à Southampton et à Camberley, ce qui lui permet de disposer d'une plus grande marge de manoeuvre et d'une plus grande flexibilité pour augmenter sa production au-delà de huit millions de tests par mois si nécessaire

Recherche et développement

Comme annoncé le 15 avril 2020, Novacyt s'est efforcé de remédier à la pénurie globale actuelle de réactifs d'extraction nécessaires pour réaliser les tests PCR en développant une nouvelle technologie d'extraction. Cette technologie permet d'éviter l'utilisation de billes magnétiques couramment utilisées dans ces réactifs d'extraction. Le développement d'une nouvelle méthode d'extraction « direct-to-PCR », Exsig™ Free, utilisée avant l'exécution du test COVID-19 du Groupe, supprimera ainsi le besoin de ces billes magnétiques utlisés dans ces réactifs en nombre limité et réduira considérablement le nombre d'étapes d'extraction, permettant des temps de cycle plus rapides, des débits plus élevés et des économies de coûts. La Direction du Groupe estime que cette innovation devrait faciliter l'augmentation de la capacité à réaliser les tests COVID-19, en supprimant pour les laboratoires le goulot d'étranglement actuel du traitement des échantillons. Le développement progresse et Novacyt est en bonne voie pour lancer cette nouvelle technologie d'extraction en mai 2020. Page 2 of 3

Nouvelle date de publication des résultats financiers 2019

Du fait d’une procédure de revue des états financiers rallongée à cause du COVID-19, le Groupe a l'intention de présenter ses résultats audités pour l'exercice clos le 31 décembre 2019 au cours de la semaine du 11 mai 2020.

Graham Mullis, Directeur général de Novacyt, commente :

« La visibilité du carnet de commandes va changer la dimension du Groupe et il devient de plus en plus évident que cette demande exceptionnelle pour notre test COVID-19 continuera pendant plusieurs mois. Par conséquent, nous continuons à nous assurer que nous disposons d'une capacité et d'une flexibilité suffisantes pour la production de notre test COVID-19.

Je suis fier que l'innovation reste au coeur de notre activité et le lancement prochain de notre kit d'extraction Exsig™ Free répondra à un besoin important du marché pour augmenter l’accès aux tests et la productivité pour les effectuer. C'est une période exigeante pour Novacyt, mais la transformation de nos performances financières et notre position de leader sur le marché des diagnostics cliniques nous rendent confiants dans les perspectives à long terme du Groupe. »


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Aussichten und Zwischenbilanz zur COVID-19-Pandemie

Article about Aussichten und Zwischenbilanz zur COVID-19-Pandemie

Wie aktuelle Daten zeigen, haben Nordamerika und Europa besonders schlecht (d. h. verspätet) auf die COVID-19-Pandemie reagiert. Zudem ist die Interpretation der Daten auch nicht immer einfach.

Während der US Präsident Donald Trump - wie auch das BAG - viel zu spät reagiert haben und jetzt zu dümmsten Zeitpunkt während einer laufenden Pandemie der WHO die Mittel entzieht, wurden jedoch durch die WHO - 

Viele Wirtschaftszweige, wie bspw. der Sportbereich, haben riesen Einbussen.

Wie geht es weiter

  • Man kann aus Simulationen die Erkenntnis gewinnen, dass das Problem wohl noch lange nicht gelöst ist, sondern zumindest ein effektives Medikament benötigt wird, bis zu eine geeigneter Impfstoff gefunden wird. Dies wird wohl - trotz grossen Anstrengungen - wohl frühestens im Jahr 2021 für die breite Bevölkerung vorhanden sein. Bei einer möglichen Saisonalität wird somit spätestens das Winterhalbjahr 2020/2021 eine Herausforderung (bzw. für die Südhalbkugel der Winter 2020)

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Negative income tax for COVID-19 and later would make sense

Article about Negative income tax for COVID-19 and later would make sense

When we see the issues of social disparities - not only during the COVID-19 crisis - we should think about the negative income tax.

negative income tax, as Friedman saw it, would, therefore, solve two main problems: It would give people cash as opposed to in-kind benefits and have a much lower tax rate. While people would still lose benefits the more they made, with a negative income tax, they would always come out ahead with a higher income.

It doesn't solve all issues, but would be more efficient than the current system as this case study for Mongolia illustrates.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

When will we be playing sports again in a normal fashion?

Article about When will we be playing sports again in a normal fashion?


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Abgetrennte Velowege als möglicher Lichtblick nach COVID-19

Article about Abgetrennte Velowege als möglicher Lichtblick nach COVID-19

Zürich gilt als eine Stadt mit einer hohen Lebensqualität.

Allerdings gibt es einige Probleme wie:

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Lernen wir von der COVID-19-Pandemie für die angesagten Umweltkatastrophen?

Article about Lernen wir von der COVID-19-Pandemie für die angesagten Umweltkatastrophen?

Bei der (vorangekündigten) COVID-19-Krise hatte man trotz klaren Indizien viel zu spät gehandelt.

Warnende (auch prominente) Stimmen hatten schon lange davor gewarnt

Es gab natürlich auch Personen, welche dies in Zweifel gezogen haben, bzw. nicht gehandelt.

 

Es ist unübersehbar, Parallelen zu der Umweltproblematik zu sehen

 

Es wäre wohl an der Zeit, vom "Locker room talk" bzgl. Klimakrise zu wirklichem Handeln überzugehen, bevor die Schäden auch (noch) offensichtlicher werden, auch wenn es etwas länger dauert und die Konsequenzen etwas länger dauern.

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Novacit fait un contrat avec le Ministère de la Santé et des Affaires Sociales britannique pour la fourniture de tests COVID-19

Novacyt S.A.

(« Novacyt » ou la « Société »)

Contrat avec le Ministère de la Santé et des Affaires Sociales britannique pour la fourniture de tests COVID-19

Paris, France et Camberley, Royaume-Uni – 27 avril 2020 – Novacyt (ALTERNEXT : ALNOV ; AIM : NCYT), spécialiste mondial du diagnostic clinique, annonce avoir signé un contrat d’approvisionnement avec le Ministère de la Santé et des Affaires Sociales britannique (Department of Health and Social Care - DHSC) pour son test COVID-19 (CE IVD) d'amplification en chaîne par polymérase (PCR), développé par Primerdesign, la division de diagnostic moléculaire du Groupe basée au Royaume-Uni.

Selon les termes de l'accord, Novacyt fournira son test COVID-19 au DHSC pour une période initiale de six mois à compter du 4 mai 2020. Novacyt s'est initialement engagée à fournir 288 000 tests par semaine au DHSC pour une utilisation dans le cadre du National Health Service (NHS), avec la possibilité d'étendre l'accord.

Ce partenariat avec le DHSC renforce l’appui actuel de Novacyt au plan du Gouvernement britannique, qui repose sur cinq piliers, visant à augmenter le nombre de tests pour le COVID-19. Le contrat s'ajoute à la collaboration du Groupe annoncée le 8 avril 2020 avec AstraZeneca, GSK et l'Université de Cambridge dans le cadre de laquelle Novacyt s'engage à assurer un processus efficace pour depister le COVID-19, fournir son test COVID-19 et générer des données à partir des résultats.

Graham Mullis, Directeur général de Novacyt, commente :

« Novacyt s'est engagé à lutter contre la pandémie mondiale de COVID-19. Ce partenariat avec le Ministère de la Santé et des Affaires Sociales renforce la position de Novacyt comme principal fournisseur de tests COVID-19 pour le NHS. »


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

We should learn from Iceland

Also, almost some Asian countries reacted much better than countries in Europe and North America.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Neue Tattoos anstatt Masken

Article about Neue Tattoos anstatt Masken

Während man bspw. in der Schweiz entscheidende Massnahmen zur COVID-19-Eindämmung mindestens drei Wochen vertrödelt hat, ist man dafür umso schneller mit der Wiedereröffnung der Tattoostudios, Das ein neues Tattoo vielleicht nicht die höchste Priorität haben sollte, ist immerhin auch Bill Gates aufgefallen.

Die Behördenaussagen scheinen nicht sehr konsistent, bspw. wenn von Daniel Koch vom BAG immer noch behauptet wird, dass Masken eher kontraproduktiv sein sollen. Gesunder Menschenverständ wäre eine starke Waffe, die meisten sind jedoch unbewaffnet.

Aktuelle Daten zeigen kein gutes Bild.

Die Schweiz hält sich so konsistent unter den Ländern mit der höchsten COVID-19-Todesquote

 

Somit reiht sich die Schweiz unter die Staaten mit den inkompetentesten Regierungen ein.

Wie aus dem Aufsatz von Prof. Dr. med. Dr. h. c. Paul Robert Vogt hervorgeht, erstaunt dies für dies für die Schweiz auch nicht, wie bspw. auch andere Versäumnisse zeigen. 

Schweden scheint dabei zum Verwechseln ähnlich. Auch macht man eine Umverteilung von Unten nach Oben.

 

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Ziemlich klare Aussagen und Empfehlungen der Behörden bezüglich COVID-19

Article about Ziemlich klare Aussagen und Empfehlungen der Behörden bezüglich COVID-19

Klarstellung der Corona Regeln

1. Im Prinzip dürfen Sie das Haus nicht verlassen, aber wenn Sie es möchten, dann dürfen Sie es schon.

2. Masken sind nutzlos, aber Sie sollten unbedingt eine tragen, denn sie kann Leben retten.

3. Alle Läden sind geschlossen, außer die, die geöffnet sind.

4. Dieses Virus ist tödlich, aber dennoch nicht allzu beängstigend, außer dass es eventuell zu einer globalen Katastrophe führt

5. Jeder muss ZUHAUSE bleiben, aber es ist wichtig auch RAUSZUGEHEN, besonders bei Sonnenschein, aber es ist besser, nicht rauszugehen, außer natürlich für Sport, aber eigentlich NEIN ...

6. Es gibt keinen Mangel an Lebensmitteln im Supermarkt, aber es gibt viele Dinge, die fehlen und andere sind zur Zeit nicht da.

7. Das Virus hat keine Auswirkungen auf Kinder, außer auf diejenigen, auf die es sich auswirkt..

8. Tiere sind nicht betroffen, aber es gibt immer noch eine Katze, die im Februar in Belgien positiv getestet wurde, als sonst noch niemand getestet wurde, plus ein paar Tiger hier und da und selten Hunde, eigentlich keine Hunde, aber manchmal doch auch schon ...
Jegliche Oberflächen, ausser das Fell ihres Haustieres, können die Krankheit natürlich übertragen.

9. Sie werden viele Symptome haben, wenn Sie krank sind, aber Sie können auch ohne Symptome krank werden, Symptome haben, ohne krank zu sein, oder ansteckend sein, ohne Symptome zu haben, sowie visa versa.

10. Das Virus bleibt auf verschiedenen Oberflächen zwei Stunden lang aktiv, nein vier, nein sechs, nein, habe ich Stunden gesagt, vielleicht Tage? Aber es braucht eine feuchte Umgebung. Aber eigentlich nicht unbedingt.
Das Virus bleibt eigentlich nicht in der Luft, aber öfter mal schon. Vor allem in einem geschlossenen Raum..
Es handelt sich hier grundsätzlich nicht um Schmierviren aber eine Schmierinfektion wäre möglich.

11. Wir sollten so lange eingesperrt bleiben, bis das Virus verschwindet, aber es wird nur verschwinden, wenn wir eine kollektive Immunität erreichen, also wenn es zirkuliert..
Dafür dürfen wir nicht zuviel eingesperrt sein, deswegen bleiben sie besser die meiste Zeit über Zuhause.

12. Sollten Sie erkrankt gewesen sein, werden Sie möglicherweise später wieder erkranken, dazwischen sind Sie imun.

;-)

Quelle: Behördenaussagen/WhatsApp


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

2 months ago

Omnia Wellness Enters into a Share Exchange and Reorganization Agreement with Bed Therapies

Omnia Wellness, Inc. (OTC: OMWS) announced that it has entered into a Share Exchange and Reorganization Agreement with a Denver-based privately held company Bed Therapies, Inc. pursuant to the Exchange Agreement, Omnia Wellness will acquire 100% of the issued and outstanding shares of the capital stock of Bed Therapies, and the shareholders of Bed Therapies will exchange such shares for newly issued shares of Omnia Wellness.  As a result, the former shareholders of Bed Therapies would own approximately 90% of the post-transaction outstanding shares of Omnia Wellness. The closing of the transaction is expected to occur in the second quarter of 2020 and is subject to closing conditions set forth in the Exchange Agreement.

Omnia Wellness and Bed Therapies are seeking to consummate this transaction to position the combined company to better commercialize its proprietary brand and market disruptive massage technology “Solajet” (www.solajet.com), as a unique and innovative Dry-Hydrotherapy technology, which provides deep tissue suppression, therapeutic heat, and a flushing full-body “wave” stimulation, by combining 3 therapies in 1. Therapeutic treatments are designed to deliver similar patient benefits as it compares to an hour-long deep tissue massage in as little as 15 minutes at an affordable price.

In the near future, Omnia Wellness and Bed Therapies will be creating a national chain of “MassageWave® Relaxation and Therapeutic Centers”, with the first  MassageWave® centers expected to open in Q4 of 2020, and “BodyStop® Recovery Zones” which are expected to be made available at fitness clubs across the country.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

New roles in Marketing and Communications team in Skanska

Skanska commercial development business unit in CEE has created new roles within the Marketing and Communications team. Anna Wiśniewska has been appointed Marketing & Communications Director, while Alexandra Bucur and Petra Machartová have been promoted to Project Marketing & Communications Manager and Corporate Marketing Manager, respectively.

 

Skanska commercial development business unit in CEE is an office real estate market leader that operates on 10 city markets in 4 countries: Czech Republic, Hungary, Romania, and Poland. In January 2020 the company appointed a new Senior Leadership Team and initiated the process of centralizing the organization on a regional level in order to enhance cross-country cooperation, establish a regional business value creation hub, and strengthen the strategic focus on customers. New roles and appointments in the marketing and communications team are part of this process.

Anna Wiśniewska, previously Marketing & Communications Manager in Skanska’s commercial development business unit in CEE, has been promoted to Marketing & Communications Director position. In the new role, she manages a team of Marketing and Communications professionals across the business unit, i.e. in the Czech Republic, Hungary, Romania, and Poland. Anna Wiśniewska joined the company in 2011 and soon became the leader of the Marketing & Communications team, first in Poland and later on the regional level. Apart from coordinating all the marketing and communications activities, she introduced new brand products to the company and the market – Workplaces by Skanska and Futureproof Workplaces by Skanska as well as developed the Futureproof marketing strategy and created a unique product standard – Scandinavian Lobby Guidelines for the CEE region.

Alexandra Bucur, newly appointed Project Marketing & Communications Manager, is responsible for creating one project marketing and communications team for the entire business unit across the 4 countries. Project marketing and communication team will work on bringing office buildings to the market, by co-creating them, their positioning and messaging. Together with Project Management and Leasing & Sales teams, will also oversee delivering brand loyalty on each market. She has more than 12 years of experience as a professional and innovative marketer, building brands from scratch, developing products and leading diverse teams. Alexandra joined Skanska in 2016 as a Marketing and Communications Manager responsible for the Romanian and Hungarian markets. She developed and managed the marketing and communication plans for projects in these countries, while simultaneously coordinating Skanska corporate marketing and communications activities.

Petra Machartová, as a new Corporate Marketing Manager, works on the business unit level, cooperates closely with corporate communications as well as with project marketing and communications teams in order to increase projects’ awareness, create interest in the products, build and maintain brand loyalty. The main responsibilities in this role will be to create new and utilize existing marketing tools and support the key client and customer care programs as well as divestment events and materials. Petra will be responsible for the promotion of the Skanska commercial development unit portfolio to key clients and main target groups. She joined Skanska Property Czech Republic in 2012 and three years later was appointed Marketing & Communication Coordinator. Since then she managed to successfully execute the marketing and brand strategy for 5 commercial projects in Prague and support Skanska commercial development unit in the Nordics in building innovation strategy and supporting innovation culture in her assignment in Stockholm.

 

Aleksandra Markiewicz continues to be responsible for communications on CEE level and performs a new position of the Corporate Communications Manager. In this role, she is responsible for setting a centralized internal and external communications strategy for the entire commercial development business unit in CEE together with her team. She joined Skanska in 2012 as the Marketing & Communications Coordinator dedicated to projects in Wrocław, Katowice, and Kraków. Later she was given different roles within Skanska Group including an assignment in the communications team in Stockholm and managing the external communication team for three business streams in Poland (construction, residential and commercial development).


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

ViralClear Pharmaceuticals, Inc. (“ViralClear”), a subsidiary of BioSig Technologies submitted an application for Vicromax through the Coronavirus Treatment Acceleration Program

On April 16, 2020, ViralClear Pharmaceuticals, Inc. (“ViralClear”), a subsidiary of BioSig Technologies, Inc. (the “Company”), submitted an application for Vicromax (Merimepodib or MMPD) through the Coronavirus Treatment Acceleration Program (CTAP) to administer the drug to hospitalized patients with COVID-19.

Anti-viral candidate merimepodib targets RNA-dependent polymerases. The molecule has shown activity against a broad spectrum of RNA viruses and has demonstrated satisfactory safety data from over 300 patients treated for hepatitis C. Recently, ViralClear published its first pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch. A manuscript titled “The IMPDH inhibitor merimepodib suppresses SARS-COV-2 replications” was authored by Natalya Bukeryeva, Emily K. Mantlo, Rachel A. Sattler, Cheng Huang, Slododan Paessler, DVM, Ph.D of the UTMB Galveston National Laboratory and Jerome Zeldis, M.D., Ph.D of ViralClear. In-vitro studies referenced in the manuscript demonstrated that merimepodib decreased viral production by over 98%.     


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

How Masks and Protective Gear Help Taking Up Business Again

While masks have been on shortage supply, in the mean-time procurement difficulties should not be a valid excuse anymore. 

Should you face difficulties in the procurement process, please contact Mostafa Shalaby from Swiss Terahertz LLC

There are some good articles how e.g. Taiwan responded to it

Unfortunately, in Europe and North America the learning process is also in this regard very slow (also the first step was hugely delayed).


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

Simulations Help Understanding the Future of the COVID-19 Pandemic

As I did my diploma thesis in quantitative finance also in a simulation study with a scenario generation model with moment matching transformations, I truly appreciate the insights from simulation work in giving the visualization and seeing the dependencies and it might also give an outlook to when it ends.

For the COVID-19 outbreak, I have seen a few excellent - also interactive - simulations and data-based forecasting, I would like to share here, as the insights are very helpful for informed decisions with the appropriatecurrent data.

You can also check the latest data on the COVID-19 outbreak with interactive charts

or this article.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

Deutscher Gewerbebereich in hohem Ausmaß von Mietausfällen betroffen

„Unsere neue Mitgliederumfrage zeigt: Der Gewerbe-bereich ist derzeit in hohem Ausmaß von Mietausfällen betroffen. 70 Prozent der Mietausfälle stammen aus Verträgen mit dem Einzelhandel, Gastronomie und dem Hotelbereich. Hier ist in besonderem Maße staatliche Hilfe für Gewerbemieter und Vermieter erforderlich, etwa durch Ausfallbürgschaften für gestundete Mieten“, so Andreas Ibel, Präsident des BFW Bundesverbandes Freier Immobilien- und Wohnungsunternehmen, heute in Berlin. Ibel präsentierte die neue Umfrage unter den mittelständischen BFW-Mitgliedsunternehmen. Die Auswertung der bundesweiten Umfrage umfasst 230.000 Mietverhältnisse in Wohn-Segment und 16.000 Mietverhältnisse im Gewerbebereich.

Demnach haben bundesweit 19 Prozent der befragten Immobilienunternehmen Mietausfälle im Gewerbebereich. In Bayern berichten 28 Prozent der befragten Unternehmen von ausbleibenden Zahlungen von Gewerbemieten, in Berlin 20 Prozent und in Nordrhein-Westfalen 15 Prozent.

Entscheidend ist dabei aber der Blick auf die individuellen Unternehmen: Abhängig von der Zusammensetzung der Bestände und der jeweiligen Branche bietet sich hier ein sehr heterogenes Bild. „Während manche Unternehmen gar nicht oder nur in geringem Maße von Mietausfällen betroffen sind, verzeichnen andere Zahlungsausfälle bei bis zu 80 Prozent der Gewerbemietverhältnisse. Dann steht die Existenz des Unternehmens durch die ausbleibende Liquidität auf dem Spiel“, warnte Ibel.

„Was wir jetzt brauchen, ist ein Bündel an unterschiedlichen, passgenauen Maßnahmen, die gemeinsame Perspektiven für Mieter und Vermieter aufzeigen“, so Ibel weiter. „Das gilt ganz besonders für den Einzelhandel, die Gastronomie und die Hotellerie, in vom shut-down in den vergangenen Wochen am stärksten betroffen waren. Hier sind nicht nur Sofort-Hilfen, sondern längerfristige Maßnahmen für einen nachhaltigen Wiederaufbau gefragt. Ausfallbürgschaften für gestundete Mieten können dabei Sicherheit für Mieter und Vermieter schaffen.“

„Es ist der Einzelhandel, die Gastronomie und der Tourismus, die das Erscheinungsbild und das Lebensgefühl vieler Städte und Kommunen prägen“, resümiert der BFW-Präsident. „Auch wenn die jetzt beschlossenen Lockerungen bei den Öffnungen Hoffnung machen, müssen Mieter und Vermieter im Gewerbebereich noch stärker unterstützt werden. Sonst drohen neben den wirtschaftlichen Auswirkungen auch negative Entwicklungen für unsere Innenstädte und unser gesellschaftliches und kulturelles Leben!“


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

Onda Group Meets Demand for Cheaper Energy during the COVID-19 Crisis

Onda Group a Pre-eminent Player in the Southern Italy Energy Market Meets Demand for Cheaper Energy during the COVID-19 Crisis

17 April 2020, Syracuse, Sicily – Onda Group, a preeminent supplier of energy to Southern Italian businesses, homes, and local utilities, announces that it is ready to supply cheaper energy for restarting the economic engine of the region by supplying lower-cost energy alternatives for its customers. With the sharp drop in oil & gas prices and the huge disruption of the Italian economy, Onda plans to supply the region with cheaper energy alternatives that have not been seen in prices for the last 30 years. 
 
 
Cheaper energy means that the regions of Sicily, Sardegna, and the Southern Italian mainland should see a resurgence of economic activity partly due to lower energy costs provided by Onda. Onda will bring to the market a technological “Killer Application” able to collect new clients and keep them forever. A smart meter provides the consumption in €, of a single device (lamps, fridges, ovens, etc). Its name is Efficento, and it is a unique technology in the European market.

As Italy recovers from the COVID-19 pandemic, Onda is poised to help jump-start this economy by providing low-cost energy products to its customer base, and the company plans to rapidly expand and increase its market share in this region. The company CEO, Luigi Martines, states “Onda will make all efforts to sell its customers energy at low prices in order to get the Italian economy moving again. It is our responsibility as energy suppliers, to pass savings on to our customers for a quick and sustainable recovery. We expect to increase overall sales and expand our services in Sicily, Sardegna, and Southern Italy to make Onda a decisive player in the energy markets in the near future.”
 
Learn more about Efficento here
 

About Onda Group.

The Wave Group has operated in the energy trading and gas industry in Italy for about 20 years. The historical sites are on two islands, Sicily and Sardinia, and the registered office is in Rome.

Onda Group was created shortly after the market liberalization of electricity in Italy in 2003. Today, they have about 35,000 customers, mainly in the islands, and a turnover of €30 million.

Thanks to years of research (funded by European Community funds), and a partnership with Voltaware, a manufacturer of technologies, Onda Group now features a "Killer Application" in Italy and soon in Europe, able to increase sales but, more importantly, contribute to customer loyalty, the main KPI industry.

Customers of Wave, thanks to "Efficiento", will be able to know in real-time and in their bills as they consume € in individual loads in their home (fridge, oven, lights, TV, etc).


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

Die Crypto Finance AG hat erfolgreich ihre Series B-Finanzierungsrunde über CHF 14 Millionen abgeschlossen

Die Crypto Finance AG hat erfolgreich ihre Series B-Finanzierungsrunde über CHF 14 Millionen abgeschlossen. Die Finanzierung wurde vom Schweizer Investor Rainer-Marc Frey und der in Asien ansässigen Lingfeng Capital angeführt. Zusätzlich beteiligten sich mehrere bestehende sowie neue Investoren. Weiter wird Dr. Ming Shu, Partner bei Lingfeng Capital, als neues Vorstandsmitglied der Crypto Finance AG vorgeschlagen. Mit dem Abschluss dieser Runde wird die Crypto Finance Gruppe die internationale Expansion weiter vorantreiben und ihre Aktivitäten im Bereich Asset Management, Trading, Tokenisierung und Storage-Lösungen für institutionelle Anleger weiterentwickeln.

16. April 2020, Zug, Schweiz. Die Crypto Finance AG hat ihre Series B-Finanzierungsrunde über CHF 14 Millionen erfolgreich abgeschlossen. Mit diesem zusätzlichen Kapital steigt das bisher aufgenommene Kapital auf insgesamt CHF 36 Millionen. Die Gruppe kann ihre Expansion, trotz den anhaltenden Herausforderungen durch Covid-19, somit weiter ausbauen. Dies ist eine enorme Leistung und zeugt vom Erfolg des bisher erreichten und der Unternehmensstrategie. Jan Brzezek, CEO und Gründer der Crypto Finance AG, äussert sich: «Ich freue mich sehr, die Neuigkeiten über unsere Finanzierungsrunde zu verkünden. Wir können somit unsere Vision und Strategie wie geplant weiterverfolgen und auch in Zukunft marktführendes und professionelles Asset Management, Trading und Infrastrukturlösungen für digitale Anlagen anbieten.»

Die Finanzierungsrunde wurde vom renommierten Schweizer Investor Rainer-Marc Frey und dem in Asien ansässigen Private Equity Fund Lingfeng Capital angeführt. Zusätzlich teilgenommen haben mehrere bereits bestehende sowie neue Investoren aus Europa und Asien, wie auch die asiatische QBN Capital. Für die erfolgreiche Vermittlung von Investoren mit dem richtigen strategischen Fokus und Fachwissen hat das Asien-Team der Crypto Finance AG mit PricewaterhouseCoopers Limited in Hong Kong zusammengearbeitet.

«Die fortschrittliche Regulierung und das pulsierende Crypto-Ökosystem überzeugten QBN in der Schweiz zu investieren. Die Crypto Finance AG gehört zu den Besten im Crypto-Sektor und der Handel von digitalen Anlagen wird immer wichtiger. Wir können also viel vom Erfahrungsschatz in der Schweiz für die Zukunft lernen», erklärt Dr. Frank Tong von QBN Capital.

Dr. Ming Shu von Lingfeng Capital stimmt dem zu: «Das Team bei Lingfeng ist vom Management und der Strategie der Crypto Finance AG sehr beeindruckt. Wir beteiligen uns an aufstrebenden Crypto-Unternehmen, die innerhalb regulierten Rahmenbedingungen agieren und gleichzeitig eine umfangreiche Erfahrung in der traditionellen Finanzbranche haben. Wir freuen uns darauf, mit der Crypto Finance Gruppe eine Brücke zwischen Europa und Asien zu schlagen und die Annäherung von traditionellen und digitalen Anlagen zu ermöglichen.»

Bereits über 50% der Geschäftstätigkeit der Gruppe kommt von internationalen Kunden. Die neuen finanziellen Mittel werden für die weiterführende internationale Expansion, wie auch für die Weiterentwicklung von Produkten und Dienstleistungen eingesetzt. Dadurch werden weitere Kunden vom sicheren und zuverlässigen Angebot, welches die Crypto Finance Gruppe bereits heute einer wachsenden Anzahl internationalen und institutionellen Investoren zur Verfügung stellt, profitieren können.

Jan Brzezek und der Vorstand der Crypto Finance AG freuen sich, mitteilen zu können, dass Dr. Ming Shu, Partner bei Lingfeng Capital, an der Generalversammlung als neues Vorstandsmitglied der Crypto Finance Gruppe vorgeschlagen wird. Dr. Shu hat ein weitreichendes regulatorisches und Finanz-Netzwerk sowie umfangreiche operative Erfahrung mit multinationalen Finanzinstitutionen, wie Henderson Global Investors oder Alibaba.
 
Über Lingfeng Capital
Lingfeng Capital ist ein Private-Equity-Fonds im Bereich Wachstumskapital für die FinTech-Branche im asiatisch-pazifischen Raum, insbesondere im Grossraum China. Fokussiert ist Lingfeng Capital auf reale Anwendungen und zugehörigen Technologien für die Finanzindustrie. Ihre Vision ist der führende Fonds im Bereich Innovationstechnologie im Finanzbereich zu werden und der neusten Generation von unternehmerisch-denkenden Fintechs Wachstum und Erfolg zu ermöglichen. Lingfeng Capital
 
Über QBN Capital
QBN Capital ist ein technologie-fokussierter Fonds, der sich auf Fintech- und Deep-Tech-Unternehmen spezialisiert hat, welche das Ziel und Potential haben, ihre Geschäftstätigkeit nach China zu skalieren. Sie bieten Portfolio-Unternehmen mit ihren Investoren- und Businessnetzwerken in dieser Region tatkräftige Unterstützung. QBN Capital
 
Über die Crypto Finance Gruppe
Die Crypto Finance Gruppe bietet institutionellen und professionellen Investoren Produkte und Dienstleistungen, welche im Crypto-Bereich weltweit führend sind. Zur Gruppe gehören die Holdinggesellschaft Crypto Finance AG, mit Sitz im Crypto Valley in der Schweiz, und die drei operativen Tochtergesellschaften: Die Crypto Fund AG, der erste von der FINMA zugelassene Vermögensverwalter für Crypto-Assets; die Crypto Broker AG, welche im 24/7 Handel mit Crypto-Assets tätig ist; und die Crypto Storage AG, welche Infrastruktur- und Tokenisierungslösungen für Crypto-Assets bereitstellt. Das mehrfach ausgezeichnete Schweizer Fintech-Unternehmen hat erfolgreich die Brücke zwischen der traditionellen Finanzwelt und den digitalen Anlagen gebaut. Crypto Finance Group

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

TradeStation Crypto Connects to ErisX to Further Increase Trading Liquidity

TradeStation Crypto expands its connectivity with the addition of ErisX quotes and liquidity to its platform

 

PLANTATION, Fla. - TradeStation Crypto, Inc. (“TradeStation Crypto”), a subsidiary of TradeStation Group, Inc. (“TradeStation Group”), announced yesterday that customers have access to quotes and liquidity from ErisX’s spot market for digital assets including Bitcoin (BTC), Bitcoin Cash (BCH), Ether (ETH) and Litecoin (LTC). This combined effort furthers TradeStation Crypto’s goal to expand its connectivity in order to provide traders with better price visibility, deeper liquidity, and streamlined access to the crypto markets.

 

“We are thrilled to add ErisX’s quotes and liquidity to our service. Adding this digital-asset exchange relationship helps improve our customers’ view of prices across more connected markets,” said James Putra, Director of Product Strategy, TradeStation Crypto. “At TradeStation Crypto, our goal is to deliver one of the deepest liquidity pools in the crypto market, and this new collaboration with ErisX is a key element of our strategy as we look to achieve that goal.”

 

TradeStation Crypto unlocks access to cryptocurrency trading through the trusted and familiar TradeStation brand, an established name in the online trading technology and brokerage industry for active and serious traders. The TradeStation brand brings a mature market mindset to the crypto markets and seeks to provide self-directed traders with deeper market liquidity and innovative pricing. Through TradeStation Crypto’s new relationship with ErisX, the two companies are working together to mature the market structure and help enable mainstream access to the crypto markets.   

 

“TradeStation Crypto and ErisX share a mission to simplify access to the crypto markets and a belief that digital assets should be accessible to those investors who want to add them to their broader portfolio,” said Thomas Chippas, CEO, ErisX. “Working with an established brand like TradeStation brings our platform to a new wave of traders who crave a seamless and dependable trading experience for digital assets as they do with capital markets.”

 

To get started trading crypto, apply for an account through TradeStation Crypto’s seamless account opening process. Click here for more information.

About TradeStation Crypto, Inc.

TradeStation Crypto is a subsidiary of TradeStation Group, Inc. that offers cryptocurrency brokerage services for self-directed online traders. For more information about the benefits and features of TradeStation Crypto, please visit www.tradestationcrypto.com.

About TradeStation Group, Inc.

For more than 30 years, the TradeStation Group companies have been pioneering leaders in the online trading industry, committed to delivering the best trading technology, brokerage services, trading education, and support to individual and institutional traders. TradeStation’s award-winning trading and analysis platforms offer access to equities, options and futures trading at the major U.S. equities and options exchanges and market centers, as well as the major futures exchanges. TradeStation’s clients have access to the powerful tools needed to design, test, optimize, monitor and automate custom trading strategies, and its mobile and web trading apps allow clients to take the power of the TradeStation trading experience on the go.  TradeStation also provides a vast array of educational offerings to help beginning and advanced clients learn online trading and investing skills to help them meet their trading and investment objectives.

TradeStation Group has a minority non-controlling ownership interest in ErisX.

About ErisX

ErisX offers individuals and institutions a single, innovative platform to access digital asset spot and futures markets. By combining professional tools, advanced technology, sophisticated regulatory oversight, and a diverse product set, ErisX offers compliant, capital markets friendly workflows to digital market participants. Backed by some of the world’s largest trading firms and financial institutions, ErisX brings transparency and reliability to the digital asset class. ErisX, Eris Exchange, and the ErisX and Eris Exchange logos are trademarks of the Eris Exchange group of companies.

ErisX Futures are offered through Eris Exchange, LLC, a Commodity Futures Trading Commission (CFTC) registered Designated Contract Market (DCM) and Eris Clearing, LLC, a registered Derivatives Clearing Organization (DCO).  The CFTC does not have regulatory oversight authority over virtual currency products including spot market trading of virtual currencies.  ErisX Spot Market is not licensed, approved or registered with the CFTC and transactions on the ErisX Spot Market are not subject to CFTC rules, regulations or regulatory oversight. ErisX Spot Market may be subject to certain state licensing requirements.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

Pilates


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

Todos Medical Expands on COVID-19Distribution Agreement with Shanghai Liangrun Subsidiary Gibraltar

Todos Medical Ltd. (TOMDF), a pre-commercial stage in vitrodiagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, announces that its President and Chief Executive Officer Gerald E. Commissiong has provided the following corporate update on the Company’s ongoing initiatives, including progress with its novel coronavirus (COVID-19) joint venture Corona Diagnostics, LLC,  the ongoing breast cancer commercialization trial with its proprietary blood spectroscopy platform, and the pending acquisition of its Alzheimer’s disease joint venture Breakthrough Diagnostics, Inc." type="text" style="margin: 10px 0;padding: 0;mso-line-height-rule: exactly;-ms-text-size-adjust: 100%;-webkit-text-size-adjust: 100%;color: #202020;font-family: Helvetica;font-size: 16px;line-height: 150%;text-align: left;">Todos Medical Ltd. (TOMDF), a pre-commercial stage in vitrodiagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, announces that its President and Chief Executive Officer Gerald E. Commissiong has provided the following corporate update on the Company’s ongoing initiatives, including progress with its novel coronavirus (COVID-19) joint venture Corona Diagnostics, LLC,  the ongoing breast cancer commercialization trial with its proprietary blood spectroscopy platform, and the pending acquisition of its Alzheimer’s disease joint venture Breakthrough Diagnostics, Inc.

Our distribution partner Gibraltar Brothers have entered into agreements to diversify its manufacturing supplies of Ab POC Test Kits for U.S. and select international sales to also include two additional POC Test Kits whose manufacturers have both already notified the U.S. Food and Drug Administration (FDA) of an Emergency Use Authorization (EUA) application, as well have both already received full Chinese National Medical Products Administration (NMPA) approval. Through our entities and teams in the U.S., Israel, and Singapore, we are working through the various regulatory and international import/export requirements in order to initiate sales in the United States and abroad. Given the tremendous competitive international demand for these Ab POC Test Kits, we felt it was important to accelerate corporate EUA-related application timelines so that we can begin discussions in earnest with prospective clients, as well as diversify our POC antibody test kit supply chain to ensure the timely delivery once orders are placed. We will seek to continue to expand this supply chain as we prepare for commercial launch, and continue to stay on the leading edge of the technology in the Ab POC Test Kit market given the rapidly evolving regulatory and international trade landscape in this field.

We are working with a leading pulmonologist in Southern California to clinically validate the initial fingerprick Ab POC Test Kit to which we gained rights last month. We expect to complete that validation process in the near future, after which we will notify the FDA of our prospective EUA application on behalf of Shanghai Liangrun’s original manufacturer later this month within the 15-day post-commercial launch window allowed by the FDA under EUA serology test guidelines. We have developed a strong working relationship with Shanghai Liangrun’s team and believe there may be areas for further collaboration in the future. We believe emerging concerns about the clinical utility of these Ab POC Test Kits will be overcome with proper US-based clinical validation to determine the most sensitive among them, innovation in the space with regards to the scientific literature evaluating other antibodies of interest in the future, as well as proper education regarding best practices for use by healthcare providers (HCPs), and therefore are also focused on engaging with HCPs to educate them on the appropriate role Ab Test Kits can play in the quickly evolving COVID-19 testing paradigm.  We also believe there will be a significant opportunity to use these Ab POC Tests for potential at-home testing strategies in combination with HCPs’ monitoring test administration and recording of results once the various appropriate safeguards are put in place to overcome the regulatory impediments that currently exist in the US. 

One of the biggest advantages of Ab POC Test Kits is that we will be able to identify those who have been previously exposed to COVID-19, as well as begin to understand whether this prior exposure confers immunity, or if long-term side effects emerge. This will be critically important as populations seek to begin to de-escalate isolation strategies so that we can understand who is most at-risk for initial infection, as well as monitor individuals for potential reinfection. While IgM is generally believed to upregulate in the blood roughly 2-7 days after initial infection and downregulate within 3-4 weeks after initial infection, IgG appears to upregulate roughly 10 days post-infection and may remain upregulated for significantly longer. It is believed IgG could remain upregulated for as long as three years post-infection, as has been seen in response to other viral infections. These biomarkers could be used to help establish individuals’ “COVID status,” thus presenting tremendous potential as a key tool as we seek to return to normal life. We believe, as do several experts in the field, that these biomarkers should be explored on a population basis in order to understand the true spread of the virus, and therefore we believe there will be a long-lasting opportunity for Todos to make a meaningful long-term impact for the benefit of our communities.

Despite certain unavoidable export delays in getting the shipment of 3DMed’s proprietary ANDiS®350 3DMed Automated Solution countertop real-time PCR (polymerase chain reaction) machine (3D Machine) and related RT-PCR test kits out of China, we are now preparing to receive those machines and complete the validation of the automation component of our PCR test kit strategy in our partner Provista’s lab in Alpharetta, GA as part of the research validation studies required for CLIA certification. We have reviewed the specifications of dozens of other PCR test kit manufacturers, and believe 3DMed’s systems may be one of the best systems on the market due to its ability to consistently detect very low viral copy count. While some POC PCR systems provide physicians with ease of use, we have identified the increased potential among those other systems for false negatives as high viral copy count specifications may result in missed early (or late) diagnosis due to the virus being present in low concentration in the oropharyngeal or nasopharyngeal structures at the time of sample collection. As such, we are taking the approach that a simple antibody blood screening tool may be helpful, in combination with other risk factors, in stratifying the patient population ahead of advancing patients to more sensitive diagnostic PCR testing with 3DMed’s systems and reagents.

Additionally, given that 3DMed is able to test for COVID-19, as well as influenza A and influenza B, there is a potentially reduced risk of retesting and/or readmission of a patient with a negative COVID-19 test result because many of those negative patients, who have historically suffered from the flu which presents with clinical symptoms similar to COVID-19, would not receive a definitive diagnosis without this additional influenza A or influenza B nucleic acid test. As a result, they would likely need to come back to the physician for additional testing, thereby putting further strain on already-stretched healthcare systems at the current time, while also putting themselves and others at increased risk of infection. 

We also have begun non-automated PCR validation in the lab because we are now evaluating offering COVID-19 stool testing service given the emerging body of evidence that suggests the virus may reside in the gastrointestinal (GI) tract while the viral load in the upper respiratory tract is in decline. Additionally, there is significant heterogeneity in the individual operator oropharyngeal or nasopharyngeal samples collection process in addition to patient heterogeneity of oropharyngeal or nasopharyngeal viral load at different time points in the course of the disease. These challenges lead to potential false negatives and create more opportunities for the virus to spread. This GI tract approach requires further validation to fully understand its impact on disease diagnosis, monitoring, and prognosis.

The objective with this dual Ab POC Test kit/PCR strategy is to establish a highly scalable protocol using the antibody test kits to help physicians quickly triage patients into risk categories (high risk, medium risk, low risk, no risk) using the IgM/IgG test, in combination with clinical symptoms and other measures, and advance only those at higher risk based on policymakers’ decision-making to guide access to PCR testing.  This would allow policymakers to focus on limited PCR testing resources on patients at higher risk of poor outcomes to the more expensive and invasive PCR testing. We believe with this strategy that we can increase patient throughput for HCPs and begin to reduce the backlog on the PCR testing system, while simultaneously improving PCR testing throughput with 3DMed’s automated extraction platform, in addition to the other platforms that are coming online. We believe that many governments, HCPs, and payors (self-insured employers and insurance companies) will be looking for comprehensive testing solutions that will allow them to reintegrate people back into the workforce, and as such being a “one-stop-shop” for all testing needs could be a valuable niche in the long run. In the short term, this strategy will allow us to broadly distribute the POC antibody test kits to HCPs while reflexing positive results to PCR testing and work to develop compliant telemedicine solutions that allow for the use the POC test kits at home where potentially two consecutive negative tests several days apart could provide the initial certification to get back to work. We intend to provide further clinical and commercial updates as key milestones in this program are achieved.

The Company has continued to advance its ongoing European pre-commercial breast cancer clinical trial in Romania investigating our proprietary TBIA spectroscopy platform using Fourier Transformed Infrared Analysis (FTIR) with our European commercial partner Orot+ (a division of Luces-Orot). The ongoing clinical trial for our breast cancer screening tests for dense breasts (TMB-2) and for all breast densities (TMB-1) has recruited nearly 50% of the subjects needed to satisfy the requirements for commercial launch in Europe under our CE mark, despite a significant recent slowdown due to COVID-19. We expect to complete enrollment for this study later in the year, with an expected launch immediately thereafter. 

Concurrent with today’s update, the Company is announcing that it has received a notice of allowance from the U.S. Patent & Trademark Office covering the use of our TBIA FTIR platform to identify benign ovarian tumors. This pending patent issuance complements our existing intellectual property portfolio that covers the use of our TBIA FTIR platform to detect malignant solid tumors. 

To complete the acquisition of Breakthrough Diagnostics due to the tremendous potential of the LymPro Test™ as a diagnostic blood test for Alzheimer’s disease. We have commissioned an independent third-party valuation of LymPro in order to fulfill the necessary requirements to complete the acquisition later this quarter. We believe that a blood test for Alzheimer’s disease remains one of the most elusive and valuable diagnostic tests sought by medical professionals. We further believe that our solution may fundamentally impact how we address Alzheimer’s disease by allowing for early diagnosis and early enrollment into clinical trials.  It may also assist in the development of new therapeutic strategies that have greater success in treating Alzheimer’s disease at its earliest stages, prior to significant brain damage.

We remain on track to complete the proposed listing of Todos’ shares onto the Nasdaq CM™ marketplace, as well as complete the acquisition of Provista Diagnostics in the second quarter of 2020 to gain ownership of its proprietary commercial-stage negative predictive value breast cancer blood test Videssa® and its CLIA/CAP certified lab. 

At the beginning of this year, we certainly did not expect to be entering the second quarter with a key focus on a novel viral disease that caused a global pandemic. Notwithstanding this, we saw the tremendous need to bring our diagnostic expertise to the forefront to combat this complex virus, and believe our expertise could help mitigate the overwhelming economic destruction COVID-19 has unleashed on world economies, in particular in the United States. We believe we are well-positioned to execute upon our diagnostic testing paradigm, which is ultimately quite similar to other testing paradigms we are developing for cancer and Alzheimer’s disease, and are proud to stand in solidarity with our colleagues in the fight against COVID-19. As we look to make an impact on this disease by bringing our expertise to bear, we are in awe at our colleagues in the scientific, medical and policymaking fields who have all rallied around this global fight against the virus. We believe that this is a fight we can contribute to and that together with our colleagues in the scientific, medical and policy fields we can win.

Lastly, they continue to work toward a NASDAQ listing for Todos’ common stock in the second quarter of 2020. I thank you for taking the time to read this update and look forward to sharing progress with you as we move forward.

Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses can be transmitted between animals and people and evolve into strains not previously identified in humans. On January 7, 2020, a novel coronavirus (SARS-CoV-2) was identified as the cause of pneumonia cases in Wuhan, Hubei Province of China, and additional cases have been found in a growing number of countries worldwide. COVID-19 is a disease caused by SARS-CoV-2.

TOMDF engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the second quarter of 2020. engineers life-saving diagnostic solutions for the early detection of a variety of cancers. The Company's state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer's influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos' two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a CE mark in Europe and are currently in a pre-commercial study with its distribution partner Orot+ (a division of Luces-Orot). Todos recently entered into an exclusive option agreement to acquire U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab and Provista's proprietary commercial-stage Videssa® breast cancer blood test. The transaction is expected to close in the second quarter of 2020.

AMBS), Todos is also actively involved with the development of blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. Todos expected to complete the remaining unowned interest in Breakthrough in the second quarter of 2020."

Todos recently entered into distribution agreements with China-based companies to distribute certain novel coronavirus (COVID-19) test kits. The Company has entered into distribution agreements covering the U.S. and Israel with Gibraltar Brothers & Associates, LLC, a U.S.-based subsidiary of Shanghai Liangrun Biomedicine Technology Co. (Shanghai), for its proprietary colloidal gold immunochromatography (Colloidal Gold) point-of-care IgM/IgM-based antibody test kits, and with 3DMedicine Science & Technology Co (3DMed), a China-based cancer precision medicine company, for distribution in the U.S. and Israel of its ANDiS® SARS-CoV-2 Detection Kit (COVID), ANDiS® SARS-CoV-2 & Influenza A/B Detection Kit (COVID/Flu) and its proprietary ANDiS®350 3DMed Automated Solution countertop real-time PCR machine (3D Machine). Todos has formed Corona Diagnostics, LLC, a joint venture with Emerald Organic Products, Inc.  (EMOR), to support the commercialization of its COVID-19 testing paradigm.

Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

 
 

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

Citius Pharmaceuticals signed contract for ARDS treatment with Novellus

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, signed an exclusive six-month option agreement to in-license a stem-cell therapy for acute respiratory distress syndrome (ARDS) from a subsidiary of Novellus, Inc., a preclinical-stage biotechnology company based in Cambridge, MA.

Novellus's patented process uses its exclusive non-immunogenic synthetic messenger ribonucleic acid (mRNA) molecules to create induced pluripotent stem cells (iPSCs) that, in turn, generate mesenchymal stem cells (MSCs) with superior immunomodulatory properties. MSCs have been shown to be safe in over 900 clinical trials and to be safe and effective in treating a number of inflammatory diseases, including ARDS.

"ARDS is the most common cause of respiratory failure and mortality in COVID-19 patients. Currently, there is no proven treatment for ARDS. Literature supports the use of counter-inflammatory MSCs for ARDS, and papers published in China have shown that at least seven COVID-19 patients with ARDS responded to MSC therapy. Clearly this is an avenue that shows promise and should be pursued as a potential treatment for ARDS. We believe Novellus is at the forefront of creating allogeneic, iPSC-derived MSCs. These cells have the potential to overcome the limitations of MSCs derived from adult donors, which are telomere shortened and introduce variability into the manufacturing process," said Citius Chief Executive Officer Myron Holubiak.

Novellus Chief Science Officer Matt Angel, Ph.D., stated, "Using our mRNA-based cell-reprogramming technology, Novellus can provide a near-unlimited supply of MSCs for treating patients with ARDS, including those critically ill from COVID-19. These will be allogeneic ('off-the-shelf') cells that in vitro have demonstrated much greater expansion potential and much higher immunomodulatory protein expression than donor-derived MSCs. We are excited to employ our technology to such an urgent medical crisis and believe that our MSCs represent an ideal source of cells to be used in this extremely important development effort."

Holubiak added, "No effective pharmacotherapy for ARDS exists, and ARDS-related morbidity and mortality are high. MSCs have been studied in the treatment of lung injury, and we aim to build upon this work with Novellus's iPSC-derived MSCs to improve the immunomodulatory response in humans. We have assembled a team of experts who are dedicated to advancing this project to an Investigational New Drug (IND) application as quickly as possible."  

About ARDS
Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by the rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients – most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain, particularly while inhaling, and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

About Citius Pharmaceuticals, Inc.
Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit www.citiuspharma.com.

About Novellus, Inc.
Novellus is a pre-clinical stage biotechnology company developing engineered cellular medicines using its non-immunogenic mRNA, nucleic-acid delivery, gene editing, and cell reprogramming technologies. Novellus is privately held and is headquartered in Cambridge, MA. For more information, please visit www.novellus-inc.com.

 

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

Fluxus CEO Fanyu Lin to serve on World Economic Forum’s Global Internet of Things Council

 

 

Fluxus CEO Fanyu Lin will serve on the World Economic Forum’s Global Internet of Things (IoT) Council, to help steward the Forum’s effort in shaping the global agenda on IoT at a time of rising public interest in the technology’s social and economic implications.

“The rapid spread of coronavirus has shaken our businesses, our governments, and our societies. It has also underscored the critical role that technology and technology governance can – and must – play in strengthening our global resilience and readiness in times of crisis. 

Now, more than ever, we need global leaders from government, industry, the start-up community, civil society, and academia to come together to provide strategic guidance to the international community on governance and cooperation priorities for emerging technologies. There is currently no place in the international system where this kind of high-level, strategic dialogue on the governance of IoT across stakeholders and regions takes place on an ongoing basis.”

– Jeff S. Merritt, Head of Internet of Things, Robotics and Smart Cities, World Economic Forum

It is estimated by Cisco that IoT can inject $14 trillion of economic value to the global economy by 2030. According to the Council’s research, issues related to how the benefits of IoT will be distributed fairly in society are identified as the largest governance gap. The Council is driving collective actions towards reaching a global baseline consensus on governance across the IoT ecosystem to maximize the positive benefits and minimize harm economically, socially and environmentally, for all of society.

“From intelligent manufacturing to grid optimization to our connected homes, the incremental adoption of IoT in housing-related industries is not only paving ways for a smarter construction model to occur, but also pushing the boundaries of what a smart home can mean for communities from the bottom of the pyramid across the economic spectrum.” – Fanyu Lin, CEO of Fluxus.

 

 

 

Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

Possible treatments for COVID-19

Article about Possible treatments for COVID-19

Will one of these drugs give remedy?


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

When will a vaccine for COVID-19 be here?

Article about When will a vaccine for COVID-19 be here?

There are also some vaccine trackers

 

and the interactive charts show COVID-19 will stay annoying for quite some time and will cause huge required efforts.

So let's hope for relief by a vaccine.


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

Interactive charts with current data for COVID-19

You can choose the countries in the charts, and also change the scale logarithmic/linear

        •  

 

Thanks to the authors/source

Max Roser, Hannah Ritchie and Esteban Ortiz-Ospina (2020) - "Coronavirus Disease (COVID-19) – Statistics and Research"

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

Interaktive Charts zur COVID-19-Pandemie mit aktuellen Zahlen

In den Graphen kann man Länder wählen, die Skala (logarithmisch/linear) wählen, die Datenquelle anschauen etc. für die Schweiz gibt es auch noch eine detaillierte Datenquelle.

        • Der Ländervergleich Todesfallvergleich im Verhältnis zur Bevölkerung

        • Flacht sich die Kurve ab?

 

      • Bestätigte tägliche Todesfälle mit dreitägig rollendem Durchschnitt (meines Erachtens eine der aussagekräftigsten Kennzahlen, da relativ klar und nicht über tägliche Meldezahlen zu stark verzerrt).

      • Tote im Verhältnis zur Bevölkerung (hier Schweiz)

    • Bestätigte Todesfälle (Achtung: in China, aber auch bspw. Schweden werden wohl zuwenige gemeldet).

  • Todesfallraten (Verhältnis zu bestätigten Fällen)
  • Dies sind nur die offiziell gemeldeten/getesteten Fälle und sind wesentlich unter den wahren Fallzahlen.

        • Todesrate im Verhältnis zu postiv gestesteten

    • Testrate in Korrelation zum Alter der Verstorbenen

    • Die Altersstruktur der Länder

    • Medizinische Versorgung anhand der Bettenanzahl

    • Ärzte pro Einwohner

Es ist schwierig in der COVID-19-Krise einen Überblick über die Daten zu haben und zu bestimmen, welches die relevanten sind.

 

Herzlichen Dank an die Autoren/Quelle für diese Einsichten/Illustrierungen

Max Roser, Hannah Ritchie and Esteban Ortiz-Ospina (2020) - "Coronavirus Disease (COVID-19) – Statistics and Research"

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

Die epidemologische Kurve anhand bestätigter Fälle

Es ist schwierig in der COVID-19-Krise einen Überblick über die Daten zu haben.

Hier eine interaktive Graphik

 


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

Vergleich auf der epidemologischen Entwicklung der DACH-Länder Südeuropa und der USA mit bestätigten Toten

Es ist schwierig in der COVID-19-Krise einen Überblick über die Daten zu haben.

Hier eine interaktive, eindrückliche visualisierende Karte zum Schauen, wo wir auf der epidemologischen Kurve sindQuelle: https://ourworldindata.org/coronavirus


Martin Signer activities: Managing Director, IR, test, Testing, Testing, Participant, Partner, Media partner, Media partner, Event manager, Events, Tester, Event listing, Tester, IR, IR, Test, Managing Director, IR, IR, IR, IR Partner, Partner, Employer, IR, IR, IR, IR, IR, IR, IR, IR, Managing Director, Managing Director, IR

Martin Signer

3 months ago

Szenariogenerierungstechnik mit Momentanpassungstransformationen für die stochastische Modellierung der COVID-19-Pandemie

Ich hatte meine Lizenziatsarbeit in Quantitative Finance zum Thema der stochastischen Modellierung mittels Szenariogenerierungstechnik mit Momentanpassungstransformationen am OperationsResearch Institut der Universität Zürich geschrieben (mit entsprechenden Simulationen).

Für die Modellierung/Simulation der verschiedenen stochastischen  Szenarien der epidemologischenKurve des COVID1Verlaufs könnte dies eine hilfreiche Quelle sein, weswegen ich sie hier gerne kostenlos zur Verfügung stelle.